Spisek izbranih novejših znanstvenih objav na temo psihedelikov in širše
(A list of selected scientific publications on the topic of psychedelics and related issues)
Za obširnejšo bibliografijo si lahko pomagate z iskalniki MAPS Psychedelic Bibliography, Erowid references, PubMed in Google Scholar. Če potrebujete katerega od spodaj naštetih člankov, pa do ustrezne revije nimate dostopa, nam pišite po elektronski pošti.
Graf števila znanstvenih objav na posamezno leto za obdobje 1955 do 2015, ki so bile indeksirane v bibliografski bazi Web of Science pod ključnimi besedami “psychedelic”, “psychotomimetic” ali “hallucinogen”.
2018
Classic Psychedelics: An integrative review of epidemiology, mystical experience, brain network function, and therapeutics
Matthew W. Johnson, Peter S. Hendricks, Frederick S. Barrett, Roland R. Griffiths
Pharmacology & Therapeutics, v tisku, 2018. DOI: 10.1016/j.pharmthera.2018.11.010
Psychedelic Neuroscience
ur. Tanya Calvey
Elsevier, 2018.
Epidemiology of hallucinogen use in the U.S. results from the National epidemiologic survey on alcohol and related conditions III
Nadav Shalit, Jürgen Rehm, Shaul Lev-Ran
Addictive Behaviors, 2019, 89, 35-43. DOI: 10.1016/j.addbeh.2018.09.020
Mutagenicity of Ayahuasca and Their Constituents to the Salmonella/Microsome Assay
Fábio Kummrow Bianca S. Maselli Rafael Lanaro José Luis Costa Gisela A. Umbuzeiro Alessandra Linardi
Environmental and molecular mutagenesis, v tisku, 2018. DOI: 10.1002/em.22263
Self-Experiments with Psychoactive Substances: A Historical Perspective
Torsten Passie, Simon D. Brandt
V: Handbook of Experimental Pharmacology. Springer, Berlin, Heidelberg, 2018. DOI: 10.1007/164_2018_177
The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial
Steliana Yanakieva, Naya Polychroni, Neiloufar Family, Luke T. J. Williams, David P. Luke, Devin B. Terhune
Psychopharmacology, v tisku, 2018. DOI: 10.1007/s00213-018-5119-x
An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders
Marika Renelli, Jenna Fletcher, Kenneth W. Tupper, Natasha Files, Anya Loizaga-Velder, Adele Lafrance
Eating and Weight Disorders – Studies on Anorexia, Bulimia and Obesity, 2018, v tisku. DOI: 10.1007/s40519-018-0619-6
The Mercurial Life of Drugs: Psychedelics as models, risk factors, and treatments for mental disorders
Johanna Pokorny, Kris De Meyer, Philipp Haueis, Tara Mahfoud, Sam McLean
Somatospere, 2018, v tisku.
Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study
Joseph Barsuglia, Alan K. Davis, Robert Palmer, Rafael Lancelotta, Austin-Marley Windham-Herman, Kristel Peterson, Martin Polanco, Robert Grant, Roland R. Griffiths
Front. Psychol., 9, 2459. DOI: 10.3389/fpsyg.2018.02459
DMT Models the Near-Death Experience
Christopher Timmermann, Leor Roseman, Luke Williams, David Erritzoe, Charlotte Martial3, Héléna Cassol, Steven Laureys, David Nutt, Robin Carhart-Harris
Front. Psychol., 2018, 9, 1424. DOI: 10.3389/fpsyg.2018.01424
Medijski odzivi: Does DMT Model the Near-Death Experience? Despite parallels, there are profound differences between DMT and NDEs
N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function
Steven A. Barker
Front. Neurosci., 2018, 12, 536. DOI: 10.3389/fnins.2018.00536
Psychedelics, Meditation, and Self-Consciousness
Raphaël Millière, Robin L. Carhart-Harris, Leor Roseman, Fynn-Mathis Trautwein, Aviva Berkovich-Ohana
Front. Psychol., 2018, 9, 1475. DOI: 10.3389/fpsyg.2018.01475
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
Leor Roseman, David J. Nutt, Robin L. Carhart-Harris
Front. Pharmacol., 2018, 8, 974. DOI: 10.3389/fphar.2017.00974
Ibogaine: History, Pharmacology, Spirituality, & Clinical Data
Benjamin Shapiro
V: Integrative Addiction and Recovery (ed. S. Modir, G. Munoz), Oxford University Press, 2018, str. 447-462.
Motivational structure of ayahuasca drinkers in social networks
Tom John Wolff, Torsten Passie
Journal of Psychedelic Studies, 2018, 2, 89–96. DOI: 10.1556/2054.2018.010
Acute effects of ayahuasca in a juvenile non-human primate model of depression
Flávia S. da Silva, Erick A.S. Silva, Geovan M. de Sousa Jr., João P. Maia-de-Oliveira,
Vanessa de Paula Soares-Rachetti, Draulio B. de Araujo, Maria B.C. Sousa, Bruno Lobão-Soares, Jaime Hallak, Nicole L. Galvão-Coelho
Braz. J. Psychiatry, v tisku, 2018. DOI: 10.1590/1516-4446-2018-0140
Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits
Elisabet Domínguez-Clavé, Joaquim Soler, Juan C. Pascual, Matilde Elices, Alba Franquesa, Marta Valle, Enric Alvarez, Jordi Riba
Psychopharmacology, v tisku, 2018. DOI: 10.1007/s00213-018-5085-3
How do psychedelics work?
Robin L. Carhart-Harris
Current Opinion in Psychiatry, 2019, 32, 16–21. DOI: 10.1097/YCO.0000000000000467
An introduction to psychedelic neuroscience
Tanya Calvey, Fleur M. Howells
Progress in Brain Research, 2018, 242, 1-23. DOI: 10.1016/bs.pbr.2018.09.013
The renaissance in psychedelic research: What do preclinical models have to offer
Kevin S. Murnane
Progress in Brain Research, 2018, 242, 25-67. DOI: 10.1016/bs.pbr.2018.08.003
D-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders
Danilo De Gregorio, Justine P. Enns, Nicolas A. Nuñez, Luca Posa, Gabriella Gobbi
Progress in Brain Research, 2018, 242, 69-96. DOI: 10.1016/bs.pbr.2018.07.008
Common neural signatures of psychedelics: Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition
Selen Atasoy, Jakub Vohryzek, Gustavo Deco, Robin L. Carhart-Harris, Morten L. Kringelbach
Progress in Brain Research, 2018, 242, 97-120. DOI: 10.1016/bs.pbr.2018.08.009
A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder
Joseph P. Barsuglia, Martin Polanco, Robert Palmer, Benjamin J. Malcolm, Benjamin Kelmendi, Tanya Calvey
Progress in Brain Research, 2018, 242, 121-158. DOI: 10.1016/bs.pbr.2018.08.002
Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain
Felix Müller, Matthias E. Liechti, Undine E. Lang, Stefan Borgwardt
Progress in Brain Research, 2018, 242, 159-177. DOI: 10.1016/bs.pbr.2018.08.004
Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers
John Martin Corkery
Progress in Brain Research, 2018, 242, 217-257. DOI: 10.1016/bs.pbr.2018.08.005
Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosers
Thomas Anderson Rotem Petranker Le-Anh Dinh-Williams Daniel Rosenbaum Cory Weissman Emma Hapke Katrina Hui Norman Farb
PsyArXiv, 2018. DOI: 10.31234/osf.io/gk4jd
3, 4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial
Marcela Ot’alora G, Jim Grigsby, Bruce Poulter, Joseph W. Van Derveer III, Sara Gael Giron, Lisa Jerome, Allison A. Feduccia, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Michael C. Mithoefer, Rick Doblin
Journal of Psychopharmacology, 2018, 32, 1295 –1307. DOI: 10.1177/0269881118806297
Ibogaine Modifies GDNF, BDNF and NGF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits
Soledad Marton, Bruno González, Sebastián Rodríguez, Ernesto Miquel, Laura Martínez Palma, Mariana Pazos, José Pedro Prieto, Paola Rodríguez, Dalibor Sames, Gustavo Seoane, Cecilia Scorza, Patricia Cassina, Ignacio Carrera
ChemRxiv, 2018. DOI: 10.26434/chemrxiv.7261559
Role of the 5-HT2A Receptor in Self- and Other-Initiated Social Interaction in Lysergic Acid Diethylamide-Induced States: A Pharmacological fMRI Study
Preller KH, Schilbach L, Pokorny T, Flemming J, Seifritz E, Vollenweider FX
J. Neurosci., 2018, 38, 3603-3611. DOI: 10.1523/JNEUROSCI.1939-17.2018
Mimosa tenuiflora (Willd.) Poir.
Alves A.S.A., Santos G.C., Albuquerque U.P.
V: Medicinal and Aromatic Plants of South America. Medicinal and Aromatic Plants of the World, vol 5. (ur. Albuquerque U., Patil U., Máthé Á.), Springer, Dordrecht, 2018.
Research ethics aspects of experimentation with LSD on human subjects: a historical and ethical review
K.J. Bodnár, P. Kakuk,
Med Health Care and Philos, 2018, v tisku. DOI: 10.1007/s11019-018-9871-9
The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women
E. Argento, M. Braschel, Z. Walsh, M. E. Socias, K. Shannon
Journal of Psychopharmacology, 2018, 32, 1385–1391. DOI: 10.1177/0269881118798610
Whole-Brain Multimodal Neuroimaging Model Using Serotonin Receptor Maps Explains Non-linear Functional Effects of LSD
Gustavo Deco, Josephine Cruzat, Joana Cabral, Gitte M. Knudsen, Robin L. Carhart-Harris, Peter C. Whybrow, Nikos K. Logothetis, Morten L. Kringelbach
Current Biology, 2018, 28, 3065-3074.e6. DOI: 10.1016/j.cub.2018.07.083
Understanding Central Nervous System Effects of Deliriant Hallucinogenic Drugs through Experimental Animal Models
Andrey D. Volgin, Oleg A. Yakovlev, Konstantin A. Demin, Polina A. Alekseeva, Evan J. Kyzar, Christopher Collins, David E. Nichols, Allan V. Kalueff
ACS Chem. Neurosci., 2018, v tisku. DOI: 10.1021/acschemneuro.8b00433
Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics
D. E. Olson
Journal of Experimental Neuroscience, 2018, v tisku. DOI: 10.1177/1179069518800508
DARK Classics in Chemical Neuroscience: Ibogaine
Michael J. Wasko, Paula A. Witt-Enderby, Christopher K. Surratt
ACS Chem. Neurosci., 2018, 9, 2475–2483. DOI: 10.1021/acschemneuro.8b00294
Substances of Abuse and Hallucinogenic Activity: The Serotoninergic Pathway – Focus on Classical Hallucinogens and Entactogens
Matteo Lazzaretti, Gian Mario Mandolini, Alfredo Carlo Altamura, Paolo Brambilla
V: P. Brambilla, M. Mauri, A. Altamura (ur.) Hallucinations in Psychoses and Affective Disorders. Springer, Cham, 2018, str. 17-31.
The Trials of Psychedelic Therapy: LSD Psychotherapy in America
Matthew Oram
Johns Hopkins University Press, 2018.
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study
Alicia L. Danforth, Charles S. Grob, Christopher Struble, Allison A. Feduccia, Nick Walker, Lisa Jerome, Berra Yazar-Klosinski, Amy Emerson
Psychopharmacology, 2018, 235, 3137–3148. DOI: 10.1007/s00213-018-5010-9
Entheogenic Spirituality: Exploring Spiritually Motivated Entheogen Use Among Modern Westerners
Petter G. Johnstad
Journal of Ethnographic & Qualitative Research, 2018, 12, 244–260.
Ayahuasca and the Healing of Eating Disorders
Marika Renelli, Jenna Fletcher, Anja Loizaga-Velder, Natasha Files, Kenneth Tupper, Adele Lafrance
V: Embodiment and Eating Disorders, (ur.) Hillary L. McBride, Janelle L. Kwee, Routledge, New York, 2018.
The hypothesis on the presence of entheogens in the Eleusinian Mysteries
Jacopo Bizzotto
Medicina Historica, 2018, 2, 85-93.
Therapeutic Potential Ascribed to Ayahuasca by Users in the Czech Republic
Miroslav Horák, Lea Hasíková, Nahanga Verter
Journal of Psychoactive Drugs, 2018, 50, 430-436. DOI: 10.1080/02791072.2018.1511878
The influence of therapists’first-hand experience with psychedelics onpsychedelic-assisted psychotherapy research and therapist training
Elizabeth M. Nielson, Jeffrey Guss
Journal of Psychedelic Studies, 2018, 2, 64–73. DOI: 10.1556/2054.2018.009
Psychedelics and psychotherapy in Canada: Humphry Osmond and Aldous Huxley
Dyck, Erika Farrell, Patrick
History of Psychology, 2018, 21, 240-253. DOI: 10.1037/hop0000088
A Single Dose of 5-MeO-DMT Stimulates Cell Proliferation, Neuronal Survivability, Morphological and Functional Changes in Adult Mice Ventral Dentate Gyrus
Lima da Cruz RV, Moulin TC, Petiz LL, Leão RN
Front. Mol. Neurosci., 2018, 11, 312. DOI: 10.3389/fnmol.2018.00312
LSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice
Kenneth Alper, Bin Dong, Relish Shah, Henry Sershen, K. Yaragudri Vinod
Front. Pharmacol., 2018, 9, 994. DOI: 10.3389/fphar.2018.00994
Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution
M.V. Uthaug, K. van Oorsouw, K.P.C. Kuypers, et al.
Psychopharmacology, 2018, 235, 2979. DOI: 10.1007/s00213-018-4988-3
It’s Tea Time: Interference of Ayahuasca Brew on Discriminative Learning in Zebrafish
Lobao-Soares B, Eduardo-da-Silva P, Amarilha H, Pinheiro-da-Silva J, Silva PF, Luchiari AC
Front. Behav. Neurosci., 2018, 12, 190. DOI: 10.3389/fnbeh.2018.00190
Plant based assisted therapy for the treatment of substance use disorders – part 1. The case of Takiwasi Center and other similar experiences
Politi M., Friso F., Mabit J.
Revista Cultura y Droga, 2018, 23, 99-126. DOI: 10.17151/culdr.2018.23.26.7
Psychedelics and the media in the Visegrad countries
Orsolya Feher
Journal of Psychedelic Studies, 2018, 2, 78–88. DOI: 10.1556/2054.2018.007
Exposure to ayahuasca induces developmental and behavioral alterations on early life stages of zebrafish
Thayres S. Andradea, Rhaulde Oliveira, Muriel Lopes da Silva, Marcus Vinicius Von Zubend, Cesar Koppe Grisolia, Inês Domingues, Eloisa Dutra Caldas, AlinePic-Taylor
Chemico-Biological Interactions, 2018, 293, 133-140. DOI: 10.1016/j.cbi.2018.08.001
The Utility of Psilocybin in Managing Anxiety and Depression in Cancer Patients
Chu Hsien Lim, Brian Kangas, Jack Bergman
Journal of Young Investigators, 2018, 35, 45-49. DOI: 10.22186/jyi.35.2.45-49
Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition
Frederick S. Barrett, Theresa M. Carbonaro, Ethan Hurwitz, Matthew W. Johnson, Roland R. Griffiths
Psychopharmacology, 2018, 235, 2915–2927. DOI: 10.1007/s00213-018-4981-x
Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT)
Cameron LP, Olson DE
ACS Chemical Neuroscience, 2018, 9, 2344-2357. DOI: 10.1021/acschemneuro.8b00101
Ayahuasca turned on my mind’s eye”: Enhanced visual imagery after ayahuasca intake in a man with “blind imagination” (aphantasia)
Rafael G. Dos Santos, Scotty Enyart, José Carlos Bouso, Òscar Pares, Jaime E. C. Hallak
Journal of Psychedelic Studies, 2018, 2, 74–77. DOI: 10.1556/2054.2018.008
Psychedelics, Meditation, and Self-Consciousness
Raphaël Millière, Robin L. Carhart-Harris, Leor Roseman, Fynn-Mathis Trautwein, Aviva Berkovich-Ohana
Front. Psychol., 2018, 9, 1475. DOI: 10.3389/fpsyg.2018.01475
Predicting Responses to Psychedelics: A Prospective Study
Haijen ECHM, Kaelen M, Roseman L, Timmermann C, Kettner H, Russ S, Nutt D, Daws RE, Hampshire ADG, Lorenz R and Carhart-Harris RL
Front. Pharmacol., 2018, 9, 897. DOI: 10.3389/fphar.2018.00897
A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification
Alan K. Davis, Elise Renn, Austin-Marley Windham-Herman, Martin Polanco, Joseph P. Barsuglia
Journal of Psychoactive Drugs, 2018, 50, 287-297. DOI: 10.1080/02791072.2018.1487607
Production Options for Psilocybin: Making of the Magic
Janis Fricke, Claudius Lenz, Jonas Wick, Felix Blei, Dirk Hoffmeister
Chemistry – A European Journal, 2018, v tisku. DOI: 10.1002/chem.201802758
Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine
Lee E. Dunlap, Anne M. Andrews, David E. Olson
ACS Chem. Neurosci., 2018, 9, 2408–2427. DOI: 10.1021/acschemneuro.8b00155
Positive psychology in the investigation of psychedelics and entactogens: A critical review
Henrik Jungaberle, Sascha Thal, Andrea Zeuch, Ansgar Rougemont-Bücking, Maximilian von Heyden, Helena Aicher, Milan Scheidegger
Neuropharmacology, 2018, 142, 179-199. DOI: 10.1016/j.neuropharm.2018.06.034
Psychedelics: Where we are now, why we got here, what we must do
Sean J. Belouin, Jack E. Henningfield
Neuropharmacology, 2018, 142, 7-19. DOI: 10.1016/j.neuropharm.2018.02.018
TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: A hallucinogenic drug, a selective 5-HT2A receptor pharmacological tool, or none of the above?
Giuseppe Di Giovanni, Philippe De Deurwaerdère
Neuropharmacology, 2018, 142, 20-29. DOI: 10.1016/j.neuropharm.2017.10.004
High dose psilocybin is associated with positive subjective effects in healthy volunteers
Christopher R Nicholas, Kelsey M Henriquez, Michele C Gassman, Karen M Cooper, Daniel Muller, Scott Hetzel, Randall T Brown, Nicholas V Cozzi, Chantelle Thomas, Paul R Hutson
Paul R Hutson
Journal of Psychopharmacology, 2018, 32, 770–778. DOI: 10.1177/0269881118780713
DARK Classics in Chemical Neuroscience: Psilocybin
Haden A. Geiger, Madeline G. Wurst, R. Nathan Daniels
ACS Chem. Neurosci., 2018, 9, 2438–2447. DOI: 10.1021/acschemneuro.8b00186
Dark Classics in Chemical Neuroscience: Mescaline
Bruce K. Cassels, Patricio Sáez-Briones
ACS Chem. Neurosci., 2018, 9, 2448–2458. DOI: 10.1021/acschemneuro.8b00215
Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)
David E. Nichols
ACS Chem. Neurosci., 2018, 9, 2331–2343. DOI: 10.1021/acschemneuro.8b00043
A Systematic Study of Microdosing Psychedelics
Vince Polito, Dick Stevenson
PsyArXiv Preprints, 2018. DOI: 10.31234/osf.io/cw9qs
Mental health of a self-selected sample of psychedelic users and self-medicationpractices with psychedelics
Natasha L. Mason, Kim P. C. Kuypers
Journal of Psychedelic Studies, 2018, 2, 45–52. DOI: 10.1556/2054.2018.006
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts
T. Noorani, A. Garcia-Romeu, T. C. Swift, R. R. Griffiths, M. W. Johnson
Journal of Psychopharmacology, 2018, 32, 756–769. DOI: 10.1177/0269881118780612
Psychedelics and hypnosis: Commonalities and therapeutic implications
C. E Lemercier, D. B. Terhune
Journal of Psychopharmacology, 2018, 32, 732–740. DOI: 10.1177/0269881118780714
Sequencing the Vine of the Soul: Full Chloroplast Genome Sequence of Banisteriopsis caapi
Padmini Ramachandran, Ning Zhang, William B. McLaughlin, Yan Luo, Sara Handy, James Alan Duke, Rodolfo Vasquez, Andrea Ottesen
Genome Announcements, 2018, 6, e00203-18. DOI: 10.1128/genomeA.00203-18
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Eduardo Ekman Schenberg
Front. Pharmacol., 2018, 9, 733. DOI: 10.3389/fphar.2018.00733
The Expanding World Ayahuasca Diaspora
ur. B. C. Labate, C. Cavnar
Routledge, Mew York, 2018.
Sustained Activation of Postsynaptic 5-HT2A Receptors Gates Plasticity at Prefrontal Cortex Synapses
Coralie Berthoux, Alexander Barre, Joël Bockaert, Philippe Marin, Carine Bécamel
Cerebral Cortex, 2018, bhy064, DOI: 10.1093/cercor/bhy064
Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma
Katie L. Uhl, Chad R. Schultz, Dirk Geerts and André S. Bachmann
Cancer Cell International, 2018, 18, 82. DOI: 10.1186/s12935-018-0574-3
Pre-clinical interaction of ayahuasca, a brew used in spiritual movements, with morphine and propofol
Júlia Movilla Pires, Fúlvio Rieli Mendes, Ana Paula Salum Pires, Maurício Yonamine, José Luiz Gomes do Amaral, Elisaldo Araújo Carlini
Braz. J. Pharm. Sci., 2018, 54, e17174. DOI: 10.1590/s2175-97902018000117174
Psychedelics and Personality
Marc Aixalà, Rafael G. dos Santos, Jaime E. C. Hallak, José Carlos Bouso
ACS Chem. Neurosci., 2018, 9, 2304–2306. DOI: 10.1021/acschemneuro.8b00237
A phenomenological investigation into the lived experience of ibogaine and its potential to treat opioid use disorders
Camlin Thaddeus James, Eulert Donald, Thomas Horvath Arthur, Bucky Steven F. Barsuglia Joseph P., Polanco Martin
Journal of Psychedelic Studies, 2018, 2, 24-35. DOI: 10.1556/2054.2018.004
Psychedelic therapy as a complementary treatment approach for alcohol use disorders
Eischens Peter, Atherton William Leigh
Journal of Psychedelic Studies, 2018, 2, 36–44. DOI: 10.1556/2054.2018.005
Psilocybin and MDMA reduce costly punishment in the Ultimatum Game
Anthony S. Gabay, Robin L. Carhart-Harris, Ndaba Mazibuko, Matthew J. Kempton, Paul D. Morrison, David J. Nutt, Mitul A. Mehta
Scientific Reports, 2018, 8, 8236. DOI: 10.1038/s41598-018-26656-2
Psychedelic use and intimate partner violence: The role of emotion regulation
M. S. Thiessen, Z. Walsh, B. M. Bird, A. Lafrance
Journal of Psychopharmacology, 2018, 32, 749–755. DOI: 10.1177/0269881118771782
Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics
Dino Luethi, Matthias E. Liechti
International Journal of Neuropsychopharmacology, 2018, 21, 926–931. DOI: 10.1093/ijnp/pyy047
Total Synthesis of the Neoclerodane Diterpene Salvinorin A via an Intramolecular Diels–Alder Strategy
Yuzhou Wang, Peter Metz
Organic Letters, 2018, 20, 3418–3421. DOI: 10.1021/acs.orglett.8b01357
It’s all you! Australian ayahuasca drinking, spiritual development, and immunitary individualism
Robin Rodd
Critique of Anthropology, 2018, 38, 325–345. DOI: 10.1177/0308275X18775818
The psychedelic religion of mystical consciousness
Rick J. Strassman
Journal of Psychedelic Studies, 2018, 2, 1–4. DOI: 10.1556/2054.2018.003
What can we learn from the psychedelic renaissance?
Max Daly
Matters of Substance, 2018, 29, 22-27.
Ayahuasca and Its DMT- and β-carbolines – Containing Ingredients Block the Expression of Ethanol-Induced Conditioned Place Preference in Mice: Role of the Treatment Environment
Elisangela G. Cata-Preta, Yasmim A. Serra, Eliseu da C. Moreira-Junior, Henrique S. Reis, Natali D. Kisaki, Matheus Libarino-Santos, Raiany R. R. Silva, Thaísa Barros-Santos, Lucas C. Santos, Paulo C. R. Barbosa, José L. Costa, Alexandre J. Oliveira-Lima, Lais F. Berro, Eduardo A. V. Marinho
Front. Pharmacol., 2018, 9, 561. DOI: 10.3389/fphar.2018.00561
Harmine, a small molecule derived from natural sources, inhibits enterovirus 71 replication by targeting NF-κB pathway
Deyan Chena, Xiaoyan Tian, Xue Zou, Shijie Xu, Huanru Wang, Nan Zheng, Zhiwei Wu
International Immunopharmacology, 2018, 60, 111-120. DOI: 10.1016/j.intimp.2018.04.050
Plant Medicines, Healing and Psychedelic Science
ur. Beatriz Caiuby Labate, Clancy Cavnar
Springer, 2018. DOI: 10.1007/978-3-319-76720-8
The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
A. K. Davis, J. P. Barsuglia, R. Lancelotta, R. M. Grant, E. Renn
Journal of Psychopharmacology, 2018, 32, 779–792. DOI: 10.1177/0269881118769063
Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca
Paulo Cesar Ribeiro Barbosa, Luís F. Tófoli, Michael P. Bogenschutz, Robert Hoy, Lais F. Berro, Eduardo A. V. Marinho, Kelsy N. Areco, Michael J. Winkelman
Front. Psychiatry, 2018, 9, 136. DOI: 10.3389/fpsyt.2018.00136
Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination
O. Grimm, R. Kraehenmann, K. H. Prellerb, E. Seifritzb, F. X. Vollenweider
European Neuropsychopharmacology, 2018, 28, 691-700. DOI: 10.1016/j.euroneuro.2018.03.016
Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls
Ana C. de Menezes Galvão, Raíssa N. de Almeida, Erick A. dos Santos Silva, Fúlvio A. M. Freire, Fernanda Palhano-Fontes, Heloisa Onias, Emerson Arcoverde, João P. Maia-de-Oliveira, Dráulio B. de Araújo, Bruno Lobão-Soares, Nicole L. Galvão-Coelho
Front. Psychiatry, 2018, 9, 185. DOI: 10.3389/fpsyt.2018.00185
Biocatalytic Production of Psilocybin and Derivatives in Tryptophan Synthase‐Enhanced Reactions
Felix Blei, Florian Baldeweg, Janis Fricke, Dirk Hoffmeister
Chemistry – A European Journal, 2018, 24, 10028-10031. DOI: 10.1002/chem.201801047
Palliative Nursing and Sacred Medicine: A Holistic Stance on Entheogens, Healing, and Spiritual Care
W. E. Rosa, S. Hope, M. Matzo
Journal of Holistic Nursing, 2018. DOI: 10.1177/0898010118770302
Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
LP Cameron, CJ Benson, LE Dunlap, DE Olson
ACS Chem. Neurosci., 2018, 9, 1582–1590. DOI: 10.1021/acschemneuro.8b00134
Acute Pharmacological Effects of 2C-B in Humans: An Observational Study
Esther Papaseit, Magí Farré, Clara Pérez-Mañá, Marta Torrens, Mireia Ventura, Mitona Pujadas, Rafael de la Torre, Débora González
Front. Pharmacol., 2018, 9, 206. DOI: 10.3389/fphar.2018.00206
Psychedelics Promote Structural and Functional Neural Plasticity
Calvin Ly, Alexandra C. Greb, Lindsay P. Cameron, Kassandra M. Ori-McKenney, John A. Gray, David E. Olson
Cell Reports, 2018, 23, P3170-3182. DOI: 10.1016/j.celrep.2018.05.022
A role for enhanced functions of sleep in psychedelic therapy?
Tom Froese, Iwin Leenen, Tomas Palenicek
Adaptive Behavior, 2018, 26, 129–135. DOI: 10.1177/1059712318762735
An ontology of psychedelic entity experiences in evolutionary psychology and neurophenomenology
Winkelman Michael James
Journal of Psychedelic Studies, 2018, 2, 5–23. DOI: 10.1556/2054.2018.002
Indolethylamine-N-methyltransferase Polymorphisms: Genetic and Biochemical Approaches for Study of Endogenous N,N,-dimethyltryptamine
Jon G. Dean
Front. Neurosci., 2018, 12, 232. DOI: 10.3389/fnins.2018.00232
Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process
Antonio Inserra
Front. Pharmacol., 2018, 9, 330. DOI: 10.3389/fphar.2018.00330
Inside bad trips: Exploring extra-pharmacological factors
Ona Genís
Journal of Psychedelic Studies, 2018, 2, 53–60. DOI: 10.1556/2054.2018.001
Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up
Rafael G. dos Santos, Rafael Faria Sanches, Flávia de Lima Osório, Jaime E. C. Hallak
Arch Clin Psychiatry., 2018, 45, 22-24. DOI: 10.1590/0101-60830000000149
Behavioral Neurobiology of Psychedelic Drugs
ur. Adam L. Halberstadt, Franz X. Vollenweider, David E. Nichols
Springer, Berlin, 2018.
Synesthetic hallucinations induced by psychedelic drugs in a congenitally blind man
Sara Dell’Erba, David J. Brown, Michael J. Proulx
Consciousness and Cognition, 2018, 60, 127-132. DOI: 10.1016/j.concog.2018.02.008
Visual hallucinations and lifetime use of hallucinogen perception persisting disorder associated recreational drugs: results from a large online survey
M. Linszen, H. Kleijer, I. Sommer
European Neuropsychopharmacology, 2018, 28, S82-S83. DOI: 10.1016/j.euroneuro.2017.12.114
Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives
Giovanni Martinotti, Rita Santacroce, Mauro Pettorruso, Chiara Montemitro, Maria Chiara Spano, Marco Lorusso, Massimo Di Giannantonio, Arturo G. Lerner
Brain Sciences, 2018, 8, 47. DOI: 10.3390/brainsci8030047
Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats
Rachel R. Horsley, Tomáš Páleníček, Jan Kolin, Karel Valeš
Behav Pharmacol., 2018, 29, 530-536. DOI: 10.1097/FBP.0000000000000394
Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action
Clinton E. Canal
V: . Handbook of Experimental Pharmacology. Springer, Berlin, 2018. DOI: 10.1007/164_2018_107
The Breakthrough Experience: DMT Hyperspace and its Liminal Aesthetics
Graham St John
Anthropology of Consciousness, 2018, 29, 57-76. DOI: 10.1111/anoc.12089
Altered network hub connectivity after acute LSD administration
Felix Müller, Patrick C. Dolder, André Schmidt, Matthias E. Liechtib, Stefan Borgwardt
NeuroImage: Clinical, 2018, 18, 694-701. DOI: 10.1016/j.nicl.2018.03.005
Maternal and developmental toxicity of the hallucinogenic plant-based beverage ayahuasca in rats
Luciana Gueiros da Motta, Juliana Alvesde Morais, Ana Carolina A.M. Tavares, Leonora Maciel Sousa Vianna, Marcia Renata Mortari, Rivadávio Fernandes Batista Amorim, Rosângela R. Carvalho, Francisco José R. Paumgartten, Aline Pic-Taylor, Eloisa DutraCaldas
Reproductive Toxicology, 2018, 77, 143-153. DOI: 10.1016/j.reprotox.2018.03.002
Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats
Joshua S. Elmore, Ann M. Decker, Agnieszka Sulima, Kenner C. Ricec, John S. Partilla, Bruce E. Blough, Michael H. Baumann
Neuropharmacology, 2018, 142, 240-250. DOI: 10.1016/j.neuropharm.2018.02.033
Ergot Alkaloids and their Hallucinogenic Potential in Morning Glories
Ulrike Steiner, Eckhard Leistner
Planta Med., 2018, 84, 751-758. DOI: 10.1055/a-0577-8049
Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs
Landon M. Klein, Nicholas V. Cozzi, Paul F. Daley, Simon D. Brandt, Adam L. Halberstadt
Neuropharmacology, 2018, 142, 231-239. DOI: 10.1016/j.neuropharm.2018.02.028
Acute Intoxication following Dimethyltryptamine Ingestion
Matthew H. Bilhimer, Rachel F. Schult, Kristan V. Higgs, Timothy J. Wiegand, Rachel M. Gorodetsky, Nicole M. Acquisto
Case Reports in Emergency Medicine, 2018, 3452691. DOI: 10.1155/2018/3452691
Four Weekly Ayahuasca Sessions Lead to Increases in “Acceptance” Capacities: A Comparison Study With a Standard 8-Week Mindfulness Training Program
Joaquim Soler, Matilde Elices, Elisabeth Dominguez-Clavé, Juan C. Pascual, Amanda Feilding, Mayte Navarro-Gil, Javier García-Campayo, Jordi Riba
Front. Pharmacol., 2018, 9, 224. DOI: 10.3389/fphar.2018.00224
5-HT2A Receptors in the Central Nervous System
ur. Bruno P. Guiard, Giuseppe Di Giovanni
Springer, 2018. DOI: 10.1007/978-3-319-70474-6
The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity
Ido Hartogsohn
Front. Neurosci., 2018, 12, 129. DOI: 10.3389/fnins.2018.00129
The re-emergence of hallucinogenic research
Matthew J. Begola, Jonathan S. Dowben
Perspectives in Psychiatric Care, 2018, 54, 523-526. DOI: 10.1111/ppc.12263
Psychedelics: from pharmacology to phenomenology. An interview with David Nichols
D. Nichols, L. Roseman, C. Timmermann
ALIUS Bulletin, 2018, 2, 75-85.
Psychedelics and the essential importance of context
R. L. Carhart-Harris, L. Roseman, E. Haijen, D. Erritzoe, R. Watts, I. Branchi, M. Kaelen
Journal of Psychopharmacology, 2018, 32, 725–731. DOI: 10.1177/0269881118754710
Powerful substances in tiny amounts: An interview study of psychedelic microdosing
Petter Grahl Johnstad
Nordic Studies on Alcohol and Drugs, 2018, 35, 39–51. DOI: 10.1177/1455072517753339
Psychedelics and related drugs: therapeutic possibilities, mechanisms and regulation
H. Valerie Curran, David Nutt, Harriet de Wit
Psychopharmacology, 2018, 235, 373–375. DOI: 10.1007/s00213-017-4822-3
Unifying Theories of Psychedelic Drug Effects
Link R. Swanson
Front. Pharmacol., 2018, 9, 172. DOI: 10.3389/fphar.2018.00172
LSD Increases Social Adaptation to Opinions Similar to One’s Own
Katrin Preller, Leonhard Schilbach, Patricia Duerler, Thomas Pokorny, Franz Vollenweider
Biological Psychiatry, 2018, 83, S198. DOI: 10.1016/j.biopsych.2018.02.518
Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans
David J. Heal, Jane Gosden, Sharon L. Smith
Neuropharmacology, 2018, 142, 89-115. DOI: 10.1016/j.neuropharm.2018.01.049
Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression
Facundo Carrillo, Mariano Sigman, Diego Fernández Slezak, Philip Ashton, Lily Fitzgerald, Jack Stroud, David J. Nutt, Robin L. Carhart-Harris
Journal of Affective Disorders, 2018, 230, 84-86. DOI: 10.1016/j.jad.2018.01.006
The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions
Elizabeth M. Nielson, Darrick G. May, Alyssa A. Forcehimes, Michael P. Bogenschutz
Front. Pharmacol., 2018, 9, 132. DOI: 10.3389/fphar.2018.00132
Serotonergic psychedelics and personality: A systematic review of contemporary research
José Carlos Bouso, Rafael G. dos Santos, Miguel Ángel, Alcázar-Córcoles, Jaime E. C. Hallak
Neuroscience & Biobehavioral Reviews, 2018, 87, 118-132. DOI: 10.1016/j.neubiorev.2018.02.004
[11C]Harmine Binding to Brain Monoamine Oxidase A: Test-Retest Properties and Noninvasive Quantification
Francesca Zanderigo, Alexandra E. D’Agostino, Nandita Joshi, Martin Schain, Dileep Kumar, Ramin V. Parsey, Christine DeLorenzo, J. John Mann
Molecular Imaging and Biology, 2018, 20, 667–681. DOI: 10.1007/s11307-018-1165-3
Functional neuroimaging of psychedelic experience: An overview of psychological and neural effects and their relevance to research on creativity, daydreaming, and dreaming
Kieran C.R. Fox, Manesh Girn, Cameron C. Parro, Kalina Christoff
arXiv, 2018, 1605.07153.
Is LSD toxic?
David E. Nichols, Charles S. Grob
Forensic Science International, 2018, 284, 141-145. DOI: 10.1016/j.forsciint.2018.01.006
Taking Psychedelics Seriously
Ira Byock, Charles Grob
Journal of Pain and Symptom Management, 2018, 55, 567. DOI: 10.1016/j.jpainsymman.2017.12.019
β2-Adrenergic Receptor Activation Suppresses the Rat Phenethylamine Hallucinogen-Induced Head Twitch Response: Hallucinogen-Induced Excitatory Post-synaptic Potentials as a Potential Substrate
Gerard J. Marek, Brian P. Ramos
Front. Pharmacol., 2018, 9, 89. DOI: 10.3389/fphar.2018.00089
The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP‐treated common marmoset model of Parkinson’s disease
Ria Fisher, Louise Lincoln, Michael J. Jackson, Vincenzo Abbate, Peter Jenner, Robert Hider, Andrew Lees, Sarah Rose
Phytotherapy Research, 2018, 32, 678-687. DOI: 10.1002/ptr.6017
Ayahuasca: A risk for travellers?
Irmgard L.Bauer
Travel Medicine and Infectious Disease, 2018, 21, 74-76. DOI: 10.1016/j.tmaid.2018.01.002
Ancient Psychoactive Substances
Scott M. Fitzpatrick
University Press of Florida, Gainesville, 2018.
Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice
Tobias Buchborn, Taylor Lyons, Thomas Knöpfel
Front. Pharmacol., 2018, 9, 17. DOI: 10.3389/fphar.2018.00017
Conceptions and practices of an integrative treatment for substance use disorders involving Amazonian medicine: traditional healers’ perspectives
Ilana Berlowitz, Christian Ghasarian, Heinrich Walt, Fernando Mendive, Vanessa Alvarado, Chantal Martin-Soelch
Rev. Bras. Psiquiatr., 2018, 40, 200-209. DOI: 10.1590/1516-4446-2016-2117
The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports
Camila Sanz, Federico Zamberlan, Earth Erowid, Fire Erowid, Enzo Tagliazucchi
Front. Neurosci., 2018, 12, 7. DOI: 10.3389/fnins.2018.00007
Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing—study on P300 and mismatch negativity in healthy volunteers
Anna Bravermanová, Michaela Viktorinová, Filip Tylš, Tomáš Novák, Renáta Androvičová, Jakub Korčák, Jiří Horáček, Marie Balíková, Inga Griškova-Bulanova, Dominika Danielová, Přemysl Vlček, Pavel Mohr, Martin Brunovský, Vlastimil Koudelka, Tomáš Páleníček
Psychopharmacology, 2018, 235, 491–503. DOI: 10.1007/s00213-017-4807-2
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
Leor Roseman, Lysia Demetriou, Matthew B. Wall, David J. Nutt, Robin L.Carhart-Harris
Neuropharmacology, 2018, 142, 263-269. DOI: 10.1016/j.neuropharm.2017.12.041
Psychiatry & the psychedelic drugs. Past, present & future
James J. H. Ruckera, Jonathan Iliff, David J. Nutt
Neuropharmacology, 2018, 142, 200-218. DOI: 10.1016/j.neuropharm.2017.12.040
Use of synthetic stimulants and hallucinogens in a cohort of electronic dance music festival attendees
Amanda L. A. Mohr, Melissa Friscia, Jillian K.Yeakel, Barry K. Logan
Forensic Science International, 2018, 282, 168-178. DOI: 10.1016/j.forsciint.2017.11.017
2017
Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine
Liana Fattore, Alessandro Piva, Mary Tresa Zanda, Guido Fumagalli, Cristiano Chiamulera
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4793-4
Studies with psychedelic drugs in human volunteers
Edward M. Sellers, Myroslava K. Romach, Deborah B. Leiderman
Neuropharmacology, 2017, v tisku. DOI: 10.1016/j.neuropharm.2017.11.029
Pharmacologically and toxicologically relevant components of Amanita muscaria
Jiří Patočka, Barbora Kocandrlová
MMSL, 2017, 86,122-134. DOI: 10.31482/mmsl.2017.020
Psychoactive and Organic Effects of Banisteriopsis caapi and Diplopteris cabrerana (Cuatrec.) B. Gates in Rats
Américo Castro, Norma Ramos, Juan Rojas-Armas, Sixto González, Otilia Acha, José Raez, Donald Ramos, Julio Hilario-Vargas
Res. J. Med. Plants, 2017, 11, 86-92. DOI: 10.3923/rjmp.2017.86.92
Ayahuasca and Kambo intoxication after alternative natural therapy for depression, confirmed by mass spectrometry
Damila Rodrigues de Morais, Rafael Lanaro, Ingrid Lopes Barbosa, Jandyson Machado Santos, Kelly Francisco Cunha, Vinicius Veri Hernandes, Elias Paulo Tessaro, Cezar Silvino Gomes, Marcos Nogueira Eberlin, Jose Luiz Costa
Forensic Toxicology, 2017, v tisku. DOI: 10.1007/s11419-017-0394-5
Regulation of human research with LSD in the United States (1949-1987)
Katherine R. Bonson
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4777-4
Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey
Will Lawn, Jaime E. Hallak, Jose A. Crippa, Rafael Dos Santos, Lilla Porffy, Monica J. Barratt, Jason A. Ferris, Adam R. Winstock, Celia J. A. Morgan
Scientific Reports 7, 2017, 15201. DOI: 10.1038/s41598-017-14700-6
LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation
Rainer Kraehenmann, Dan Pokorny, Helena Aicher, Katrin H. Preller, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz, Franz X. Vollenweider
Front. Pharmacol., 2017, v tisku. DOI: 10.3389/fphar.2017.00814
Why MDMA therapy for alcohol use disorder? And why now?
Ben Sessa
Neuropharmacology, 2017, v tisku. DOI: 10.1016/j.neuropharm.2017.11.004
Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences
Theresa M. Carbonaro, Matthew W. Johnson, Ethan Hurwitz, Roland R. Griffiths
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4769-4
LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm
Christopher Timmermann, Meg J. Spriggs, Mendel Kaelen, Robert Leech, David J.Nutt, Rosalyn J.Moran, Robin L. Carhart-Harris, Suresh D. Muthukumaraswamy
Neuropharmacology, 2017, v tisku. DOI: 10.1016/j.neuropharm.2017.10.039
N,N-dimethyltryptamine and the pineal gland: Separating fact from myth
David E Nichols
Journal of Psychopharmacology, 2017, v tisku. DOI: 10.1177/0269881117736919
Additive Effects of 3,4-Methylenedioxymethamphetamine (MDMA) and Compassionate Imagery on Self-Compassion in Recreational Users of Ecstasy
S. K. Kamboj, Y. S. E. Walldén, C. J. Falconer, et al.
Mindfulness, 2017, v tisku. DOI: 10.1007/s12671-017-0849-0
Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression
J. B. Stroud, T. P. Freeman, R. Leech, C. Hindocha, W. Lawn, D. J. Nutt, H. V Curran, R. L. Carhart-Harris
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4754-y
The relationships of classic psychedelic use with criminal behavior in the United States adult population
Peter S Hendricks, Michael Scott Crawford, Karen L Cropsey, Heith Copes, N Wiles Sweat, Zach Walsh, Gregory Pavela
Journal of Psychopharmacology, 2017, v tisku. DOI: 10.1177/0269881117735685
Perceptions of the medicinal value of hallucinogenic drugs among college students
Wildberger Jared I., John Cassandra N. Hallock Robert M.
Journal of Psychedelic Studies, 2017, v tisku. DOI: 10.1556/2054.01.2017.008
Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning
Davis Alan K., Barsuglia Joseph P., Windham-Herman Austin-Marley, Lynch Marta, Polanco Martin
Journal of Psychedelic Studies, 2017, v tisku. DOI: 10.1556/2054.01.2017.009
Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT
Vanja Dakić, Juliana Minardi Nascimento, Rafaela Costa Sartore, Renata de Moraes Maciel, Draulio B. de Araujo, Sidarta Ribeiro, Daniel Martins-de-Souza, Stevens K. Rehen
Scientific Reports, 2017, 7: 12863. DOI: 10.1038/s41598-017-12779-5
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors
Roland R Griffiths, , Matthew W Johnson, William A Richards, Brian D Richards, Robert Jesse, Katherine A MacLean, Frederick S Barrett, Mary P Cosimano, Maggie A Klinedinst
Journal of Psychopharmacology, 2017, v tisku. DOI: 10.1177/0269881117731279
Investigation into pharmacokinetic properties of active alkaloid ibogaine and its metabolite noribogaine
Asta Kubiliene, Audrius Sveikata, Andrejus Zevzikovas, Ilona Sadauskiene, Leonid Ivanov
Acta Poloniae Pharmaceutica – Drug Research, 2017, 74, 1591-1597.
TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: A hallucinogenic drug, a selective 5-HT2A receptor pharmacological tool, or none of the above?
Giuseppe Di Giovanni, Philippe De Deurwaerdère
Neuropharmacology, 2017, v tisku. DOI: 10.1016/j.neuropharm.2017.10.004
Acute LSD effects on response inhibition neural networks
A. Schmidt, F. Müller, C. Lenz, P. C. Dolder, Y. Schmid, D. Zanchi, U. E. Lang, M. E. Liechti, S. Borgwardt
Psychological Medicine, 2017, v tisku. DOI: 10.1017/S0033291717002914
The Mechanisms of Psychedelic Visionary Experiences: Hypotheses from Evolutionary Psychology
Michael J. Winkelman
Front. Neurosci., 2017, v tisku. DOI: 10.3389/fnins.2017.00539
Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music
Frederick S. Barrett, Katrin H. Preller, Marcus Herdener, Petr Janata, Franz X. Vollenweider
Cerebral Cortex, 2017, v tisku. DOI: 10.1093/cercor/bhx257
Acute LSD effects on response inhibition neural networks
A. Schmidt, F. Müller, C. Lenz, P. C. Dolder
Psychological Medicine, 2017, v tisku. DOI: 10.1017/S0033291717002914
Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting
Elena Argento, Steffanie A Strathdee, Kenneth Tupper, Melissa Braschel, Evan Wood, Kate Shannon
BMJ Open, 2017, 7: e016025. DOI: 10.1136/bmjopen-2017-016025
Psychedelic Drugs in Biomedicine
Evan J. Kyzar, Charles D. Nichols, Raul R. Gainetdinov, David E. Nichols, Allan V. Kalueff
Trends in Pharmacological Sciences, 2017, v tisku. DOI: 10.1016/j.tips.2017.08.003
Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review
Simon Reiche, Leo Hermle, Stefan Gutwinski, Henrik Jungaberle, Peter Gasser, Tomislav Majić
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, v tisku. DOI: 10.1016/j.pnpbp.2017.09.012
Long-lasting subjective effects of LSD in normal subjects
Yasmin Schmid, Matthias E. Liechti
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4733-3
Longitudinal Examination of Learning and Memory in Rats Following Adolescent Exposure to 3,4-Methylenedioxymethamphetamine or 5-Methoxy-N,N-Diisopropyltryptamine
David M. Compton, Kerri L. Dietrich, Peniel Esquivel, Corina Garcia
Journal of Behavioral and Brain Science, 2017, 7, 371-398. DOI: 10.4236/jbbs.2017.79028
Serotonin and brain function: a tale of two receptors
R. L. Carhart-Harris, D. J. Nutt
J. Psychopharmacol., 2017, 31, 1091-1120. DOI: 10.1177/0269881117725915
Ayahuasca: what mental health professionals need to know
Rafael Guimarães dos Santos, José Carlos Bouso, Jaime Eduardo Cecilio Hallak
Archives of Clinical Psychiatry, 2017, 44, v tisku. DOI: 10.1590/0101-60830000000130
pregledni članek
A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment
Eduardo Ekman Schenberg, Maria Angélica de Castro Comis, João Felipe Morel Alexandre, Luís Fernando Tófoli, Bruno Daniel Rasmussen Chaves, Dartiu Xavier da Silveira
Journal of Psychedelic Studies, 2017, v tisku. DOI: 10.1556/2054.01.2017.007
MDA, MDMA and other mescaline-like substances in the US military’s search for a truth drug (1940s to 1960s)
T. Passie, U. Benzenhöfer
Drug Test Anal., 2017, v tisku. DOI: 10.1002/dta.2292
Ayahuasca, Technical Report 2017
José Carlos Bouso, Rafael Guimarães dos Santos, Charles S. Grob, Dartiu Xavier da Silveira, Dennis Jon McKenna, Draulio Barros de Araujo, Jordi Riba, Paulo Cesar Ribeiro Barbosa, Constanza Sánchez Aviléz, Beatriz Caiuby Labate
ICEERS. http://news.iceers.org/2017/07/2017-ayahuasca-technical-report/
Enzymatic Synthesis of Psilocybin
J. Fricke, F. Blei, D. Hoffmeister
Angew. Chem. Int. Ed., 2017, 56, 12352. DOI: 10.1002/anie.201705489
Medijski odzivi: Magic enzymes in ‘magic’ mushrooms analyzed
Horizontal gene cluster transfer increased hallucinogenic mushroom diversity
Hannah T. Reynolds, Vinod Vijayakumar, Emile Gluck-Thaler, Hailee B. Korotkin, Patrick B. Matheny, Jason C. Slot
bioRxiv, 2017, v tisku. DOI: 10.1101/176347
Medijski odzivi: Magic mushroom chemical may be a hallucinogenic insect repellent
Psychedelic Drugs as Therapeutics: No Illusions About the Challenges
E. M. Sellers, D. B. Leiderman
Clin. Pharmacol. Ther., 2017, v tisku. DOI: 10.1002/cpt.776
The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant
Ben Sessa
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4713-7
Pharmacological studies of Syrian rue (Peganum harmala L., Zygophyllaceae)
Nazim A Mamedov, Ardalan Pasdaran, Nilufar Z. Mamadalieva
International Journal of Secondary Metabolite, 2017, 5, v tisku. DOI: 10.21448/ijsm.335539
Naturalizing psychedelic spirituality
Letheby Chris
Zygon, 2017, 52, 623-642. DOI: 10.1111/zygo.12353
Entheogenesis: Toward an Expanded Worldview for Our Time
Ralph Metzner
Journal of Humanistic Psychology, 2017, 57, 443-449. DOI: 10.1177/0022167817723405
Psychedelics and connectedness
Carhart-Harris, R.L., Erritzoe, D., Haijen, E. et al.
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4701-y
Screening of Hallucinogenic Compounds and Genomic Characterisation of 40 Anatolian Salvia Species
Hatipoglu, S. D., Yalcinkaya, B., Akgoz, M., Ozturk, T., Goren, A. C., and Topcu, G.
Phytochem. Anal., 2017, v tisku. DOI: 10.1002/pca.2703
Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy
James W.B. Elsey
Drug Science, Policy and Law, 2017, v tisku. DOI: 10.1177/2050324517723232
Behavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish
Robson Savoldi, Daniel Polari, Jaquelinne Pinheiro-da-Silva, Priscila F. Silva, Bruno Lobao-Soares, Mauricio Yonamine, Fulvio A. M. Freire, Ana C. Luchiari
Front. Behav. Neurosci., 2017, v tisku. DOI: 10.3389/fnbeh.2017.00139
The hyperassociative mind: The psychedelic experience and Merleau-Ponty’s “wild being”
Csaba Szummer, Lajos Horváth, Attila SzabÓ, Ede Frecska, KristÓf OrzÓi
Journal of Psychedelic Studies, 2017, v tisku. DOI: 10.1556/2054.01.2017.006
Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions
Frederick S. Barrett, Hollis Robbins, David Smooke, Jenine L. Brown, Roland R. Griffiths
Front. Psychol., 2017, v tisku. DOI: 10.3389/fpsyg.2017.01238
Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs)
Dino Luethi, Daniel Trachsel, Marius C. Hoener, Matthias E. Liechti
Neuropharmacology, 2017, v tisku. DOI: 10.1016/j.neuropharm.2017.07.012
Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow
Candace R. Lewis, Katrin H. Preller, Rainer Kraehenmann, Lars Michels, Philipp Staempfli, Franz X. Vollenweider
NeuroImage, 2017, 159, 70–78. DOI: 10.1016/j.neuroimage.2017.07.020
LSD experiments by the United States Army
Colin A Ross
History of Psychiatry, 2017, v tisku. DOI: 10.1177/0957154X17717678
Developing Guidelines and Competencies for the Training of Psychedelic Therapists
Janis Phelps
Journal of Humanistic Psychology, 2017, v tisku. DOI: 10.1177/0022167817711304
MDMA-induced dissociative state not mediated by the 5-HT2A receptor
Drew J. Puxty, Johannes G. Ramaekers, Rafael de la Torre, Magí Farré, Neus Pizarro, Mitona Pujadas, Kim P. Kuypers
Front. Pharmacol., 2017, v tisku. DOI: 10.3389/fphar.2017.00455
A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects
Patrick C. Dolder, Edna Grünblatt, Felix Müller, Stefan J. Borgwardt, Matthias E. Liechti
Front. Pharmacol., 2017, v tisku. DOI: 10.3389/fphar.2017.00423
Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy
Mark T Wagner, Michael C. Mithoefer, Ann T. Mithoefer, Rebecca K. MacAulay, Lisa Jerome, Berra Yazar-Klosinski, Rick Doblin
Journal of Psychopharmacology, 2017, v tisku. DOI: 10.1177/0269881117711712
Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression
Rosalind Watts, Camilla Day, Jacob Krzanowski, David Nutt, Robin Carhart-Harris
Journal of Humanistic Psychology, 2017, v tisku. DOI: 10.1177/0022167817709585
Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness
Matthias Forstmann, Christina Sagioglou
Journal of Psychopharmacology, 2017, v tisku. DOI: 10.1177/0269881117714049
Neuroticism is associated with challenging experiences with psilocybin mushrooms
Frederick S. Barrett, Matthew W. Johnson, Roland R. Griffiths
Personality and Individual Differences, 2017, 117, 155–160. DOI: 10.1016/j.paid.2017.06.004
Potential Therapeutic Effects of Psilocybin
M. W. Johnson, R. R. Griffiths
Neurotherapeutics, 2017, v tisku. DOI: 10.1007/s13311-017-0542-y
Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes
Thomas Kingsley Brown, Kenneth Alper
The American Journal of Drug and Alcohol Abuse, 2017, v tisku. DOI: 10.1080/00952990.2017.1320802
Chronic intermittent exposure to ayahuasca during aging does not affect memory in mice
N. F. Correa-Netto, L. S. Coelho, G. S. Galfano, F. Nishide, F. Tamura, M. K. Shimizu et al.
Braz. J. Med. Biol. Res., 2017, 50, e6037. DOI: 10.1590/1414-431×20176037
An ontogenic study of the behavioral effects of chronic intermittent exposure to ayahuasca in mice
N. F. Correa-Netto, M. Y. Masukawa, F. Nishide, G. S. Galfano, F. Tamura, M. K. Shimizo et al.
Braz. J. Med. Biol. Res., 2017, 50, e6036. DOI: 10.1590/1414-431×20176036
Potential Use of Ayahuasca in Grief Therapy
Débora González, María Carvalho, Jordi Cantillo, Marc Aixalá, Magí Farré
OMEGA – Journal of Death and Dying, 2017, v tisku. DOI: 10.1177/0030222817710879
Psilocybin: Good Trip or Bad Trip
Sellers, E.
Clin. Pharmacol. Ther., 2017, v tisku. DOI: 10.1002/cpt.697
Harmine is an inflammatory inhibitor through the suppression of NF-κB signaling
Xin Liu, Mingxia Li, Si Tan, Changhong Wang, Shengjie Fan, Cheng Huang
Biochemical and Biophysical Research Communications, 2017, 489, 332–338. DOI: 10.1016/j.bbrc.2017.05.126
Ayahuasca Modifies Amphetamine Self Ingestion and Modifies Anxiety and Locomotor Activity in Adolescent Rats
A. F. Godinho, M. C. Silva, J. D. Kawashima, D. F. Horta, F. Anselmo, D. De Fraia
Electronic Journal of Biology, 2017, 13, 159-165.
Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities
F. Sampedro, M. de la Fuente Revenga, M. Valle, N. Roberto, E. Domínguez-Clavé, M. Elices, L. Eduardo Luna, J. A. S. Crippa, J. E. C. Hallak, D. B. de Araujo, P. Friedlander, S. A. Barker, E. Álvarez, J. Soler, J. C. Pascual, A. Feilding, J. Riba
Int. J. Neuropsychopharmacol., 2017, pyx036. DOI: 10.1093/ijnp/pyx036
Genie in a blotter: A comparative study of LSD and LSD analogues’ effects and user profile
L. D. Coney, L. J. Maier, J. A. Ferris, A. R. Winstock, M. J. Barratt
Hum Psychopharmacol Clin Exp., 2017, e2599. DOI: 10.1002/hup.2599
Psychedelics As A New Anti-Inflammatory Therapeutic For Atherosclerosis
Charles D. Nichols, Melaine Sebastia, Thomas Flanagan
The FASEB Journal, 2017, 31, Supplement 825.3
Elucidating Functional Selectivity at the 5-HT2A Receptor
Gerald Billac, Charles Nichols
The FASEB Journal, 2017, 31, Supplement 663.2
Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist’s Perspective
B. Sessa
Neurotherapeutics, 2017, v tisku. DOI: 10.1007/s13311-017-0531-1
Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis
Alexander B. Belser, Gabrielle Agin-Liebes, T. Cody Swift, Sara Terrana, Neşe Devenot, Harris L. Friedman, Jeffrey Guss, Anthony Bossis, Stephen Ross
Journal of Humanistic Psychology, 2017, v tisku. DOI: 10.1177/0022167817706884
The Therapeutic Potential of Psychedelic Drugs: Past, Present and Future
Robin L. Carhart-Harris, Guy M. Goodwin
Neuropsychopharmacology, 2017, v tisku. DOI: 10.1038/npp.2017.84
Psychedelics, Personality and Political Perspectives
Matthew M. Nour, Lisa Evans, Robin L. Carhart-Harris
Journal of Psychoactive Drugs, 2017, v tisku. DOI: 10.1080/02791072.2017.1312643
Detoxification from methadone using low, repeated, and increasing doses of ibogaine: A case report
Clare Wilkins, Rafael G. dos Santos, Jordi Solá, Marc Aixalá, Pep Cura, Estefanía Moreno, Miguel Ángel Alcázar-Córcoles, Jaime E. C. Hallak, Jose Carlos Bouso
Journal of Psychedelic Studies, 2017, v tisku. DOI: 10.1556/2054.01.2017.005
Anxiety, panic, and hopelessness during and after ritual ayahuasca intake in a woman with generalized anxiety disorder: A case report
Rafael G. dos Santos, Flávia L. Osório, José Alexandre S. Crippa, Ribeirão Preto, Jaime E. C. Hallak
Journal of Psychedelic Studies, 2017, 1, 35-39. DOI: 10.1556/2054.01.2017.004
Ayahuasca’s entwined efficacy: An ethnographic study of ritual healing from ‘addiction’
Piera Talin, Emilia Sanabri
International Journal of Drug Policy, 2017, 44, 23–30. DOI: 10.1016/j.drugpo.2017.02.017
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin
Michael M. Schartner, Robin L. Carhart-Harris, Adam B. Barrett, Anil K. Seth, Suresh D. Muthukumaraswamy
Scientific Reports, 2017, 7, 46421. DOI: 10.1038/srep46421
Analysis of the differences between hallucinations caused by natural hallucinogens and schizophrenia
Kristofer L. Korth
Eukaryon, 2017.
Chemistry and Structure–Activity Relationships of Psychedelics
David E. Nichols
Current Topics in Behavioral Neurosciences, 2017, v tisku. DOI: 10.1007/7854_2017_475
Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates
Frederick S. Barrett, Roland R. Griffiths
Current Topics in Behavioral Neurosciences, 2017, v tisku. DOI: 10.1007/7854_2017_474
Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation
Rainer Kraehenmann, Dan Pokorny, Leonie Vollenweider, Katrin H. Preller, Thomas Pokorny, Erich Seifritz, Franz X. Vollenweider
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4610-0
Detailed characterization of the in vitro pharmacological and pharmacokinetic properties of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine (25CN-NBOH), a highly selective and brain-penetrant 5-HT2A receptor agonist
A. A. Jensen, J. D. McCorvy, S. L. Petersen, C. Bundgaard, G. Liebscher, T. P. Kenakin, H. Bräuner-Osborne, J. Kehler, J. L. Kristensen
Journal of Pharmacology and Experimental Therapeutics, 2017, v tisku. DOI: 10.1124/jpet.117.239905
A single administration of the hallucinogen, 4-acetoxy-dimethyltryptamine, prevents the shift to a drug-dependent state and the expression of withdrawal aversions in rodents
Authors: Hector Vargas-Perez, Taryn E. Grieder, Ryan Ting-A-Kee, Geith Maal-Bared, Michal Chwalek, Derek van der Kooy
European Journal of Neuroscience, 2017, v tisku. DOI: 10.1111/ejn.13572
Hallucinogenic Drugs: A New Study Answers Old Questions about LSD
Adam L. Halberstadt
Current Biology, 2017, 27, R139–R161. DOI: 10.1016/j.cub.2016.12.058
Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects
F. Mueller, C. Lenz, P. C. Dolder, S. Harder, Y. Schmid, U. E. Lang, M. E. Liechti, S. Borgwardt
Translational Psychiatry, 2017, 7, e1084. DOI: 10.1038/tp.2017.54
Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
Randall T. Brown, Christopher R. Nicholas, Nicholas V. Cozzi, Michele C. Gassman, Karen M. Cooper, Daniel Muller, Chantelle D. Thomas, Scott J. Hetzel, Kelsey M. Henriquez, Alexandra S. Ribaudo, Paul R. Hutson
Clinical Pharmacokinetics, 2017, v tisku. DOI: 10.1007/s40262-017-0540-6
In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks
Lea Wagmann, Simon D. Brandt, Pierce V. Kavanagh, Hans H. Maurer, Markus R. Meye
Toxicology Letters, 2017, v tisku. DOI: 10.1016/j.toxlet.2017.03.007
Reproductive effects of the psychoactive beverage ayahuasca in male Wistar rats after chronic exposure
Alana de Fátima Andrade Santosa, Ana Luiza Sarkis Vieirab, Aline Pic-Taylorc, Eloisa Dutra Caldas
Revista Brasileira de Farmacognosia, 2017, v tisku. DOI: 10.1016/j.bjp.2017.01.006
Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences
Annamarie Heink, Steve Katsikas, Tiffany Lange-Altman
Journal of Psychoactive Drugs, 2017, v tisku. DOI: 10.1080/02791072.2017.1290855
Effects of Hallucinogens on Neuronal Activity
L. Lladó-Pelfort, P. Celada, M. S. Riga, E. Troyano-Rodríguez, N. Santana, F. Artigas
Current Topics in Behavioral Neurosciences, 2017, v tisku. DOI: 10.1007/7854_2017_473
Ayahuasca dimethyltryptamine, and psychosis: a systematic review of human studies
Rafael G. dos Santos, José Carlos Bouso, Jaime E. C. Hallak
Therapeutic Advances in Psychopharmacology, 2017, v tisku. DOI: 10.1177/2045125316689030
Psychedelics and the science of self-experience
Matthew M. Nour, Robin L. Carhart-Harris
The British Journal of Psychiatry, 2017, 210, 177-179. DOI: 10.1192/bjp.bp.116.194738
Effect of Hallucinogens on Unconditioned Behavior
Adam L. Halberstadt, Mark A. Geyer
Current Topics in Behavioral Neurosciences, 2017, v tisku. DOI: 10.1007/7854_2016_466
Short term changes in the proteome of human cerebral organoids induced by 5-methoxy-N, N-dimethyltryptamine
V. Dakic, J. Minardi Nascimento, R. Costa Sartore, R. de Moraes Maciel, D. B. de Araujo, S. Ribeiro, D. Martins-de-Souza, S. Rehen
bioRxiv – The preprint server for biology, 2017. DOI: 10.1101/108159
The association of psychedelic use and opioid use disorders among illicit users in the United States
V. D. Pisano, N. P. Putnam, H. M. Kramer, K. J. Franciotti, J. H. Halpern, S. C. Holden
Journal of Psychopharmacology, 2017, v tisku. DOI: 10.1177/0269881117691453
Science, spirituality, and ayahuasca: The problem of consciousness and spiritual ontologies in the academy
Ismael Apud
Zygon®, 2017, 52, 100–123. DOI: 10.1111/zygo.12315
Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
P. C. Dolder, Y. Schmid, A. E. Steuer, T. Kraemer, K. M. Rentsch, F. Hammann, M. E. Liechti
Clinical Pharmacokinetics, 2017, v tisku. DOI: 10.1007/s40262-017-0513-9
A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics
A. Cruz, S. Domingos, E. Gallardo, A. Martinho
Phytochemistry, 2017, 137, 9–14. DOI: 10.1016/j.phytochem.2017.02.001
The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation
K. H. Preller, M. Herdener, T. Pokorny, A. Planzer, R. Kraehenmann, P. Stämpfli, M. E. Liechti, E. Seifritz, F. X. Vollenweider
Current Biology, 2017, 27, 451–457. DOI: 10.1016/j.cub.2016.12.030
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomised placebo-controlled trial
F. Palhano-Fontes et al.
bioRxiv – The preprint server for biology, 2017. DOI: 10.1101/103531
Crystal Structure of an LSD-Bound Human Serotonin Receptor
Daniel Wacker, Sheng Wang, John D. McCorvy, Robin M. Betz, A.J. Venkatakrishnan, Anat Levit, Katherine Lansu, Zachary L. Schools, Tao Che, David E. Nichols, Brian K. Shoichet, Ron O. Dror, Bryan L. Roth
Cell, 2017, 168, 377–389, e12. DOI: 10.1016/j.cell.2016.12.033
The fibrinolytic system: A new target for treatment of depression with psychedelics
R. D. Idell, G. Florova, A. A. Komissarov, S. Shetty, R. B. S. Girard, S. Idell
Medical Hypotheses, 2017, 100, 46–53. DOI: 10.1016/j.mehy.2017.01.013
Determination of Tryptamines and β-Carbolines in Ayahuasca Beverage Consumed During Brazilian Religious Ceremonies
M. C. Santos, S. Navickiene, A. Gaujac
Journal of AOAC International, 2017, v tisku. DOI: 10.5740/jaoacint.16-0337
Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens
Adam L. Halberstadt
Current Topics in Behavioral Neurosciences, 2017, v tisku. DOI: 10.1007/7854_2016_64
Self-Transcendence Correlates with Brain Function Impairment
Bernardo Kastrup
Journal of Cognition and Neuroethics, 2017, 4, 33–42.
Constructing drug effects: A history of set and setting
Ido Hartogsohn
Drug Science, Policy and Law, 2017, 3, v tisku. DOI: 10.1177/2050324516683325
An online survey of tobacco smoking cessation associated with naturalistic psychedelic use
Matthew W Johnson, Albert Garcia-Romeu, Patrick S Johnson, Roland R Griffiths
Journal of Psychopharmacology, 2017, v tisku. DOI: 10.1177/0269881116684335
Weak phantasy and visionary phantasy: the phenomenological significance of altered states of consciousness
Lajos Horváth, Csaba Szummer, Attila Szabo
Phenomenology and the Cognitive Sciences, 2017, v tisku. DOI: 10.1007/s11097-016-9497-4
Clinical potential of psilocybin as a treatment for mental health conditions
Jeremy Daniel, Margaret Haberman
Mental Health Clinician, 2017, 7, 24-28. DOI: 10.9740/mhc.2017.01.024
Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?
Benjamin J. Malcolm and Kelly C. Lee (2017)
Mental Health Clinician, 2017, 7, 39-45. DOI: 10.9740/mhc.2017.01.039
A One-Dose Psychedelic Fix for Addiction?
Roni Jacobson
Scientific American Mind, 2017, 28, 10-11. DOI: 10.1038/scientificamericanmind0117-10
The Therapeutic Potential of Ayahuasca
Michael A. Coe, Dennis J. McKenna
v: Evidence-Based Herbal and Nutritional Treatments for Anxiety in Psychiatric Disorders II, 2017, str. 123-137. DOI: 10.1007/978-3-319-42307-4_7
pregledni članek
Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use
Celia Morgan, Amy McAndrew, Tobias Stevens, David Nutt, Will Lawn
Current Opinion in Behavioral Sciences, 2017, 13, 71–76. DOI: 10.1016/j.cobeha.2016.10.009
2016
The History of Psychedelics in Medicine
Ben Sessa
v: M. von Heyden et al. (ur.), Handbuch Psychoaktive Substanzen, Springer Reference Psychologie, 2016. DOI 10.1007/978-3-642-55214-4_96-1
Psilocybin-assisted psychotherapy for dying cancer patients – aiding the final trip
David Spiegel
Journal of Psychopharmacology, 2016, 30, 1215-1217. DOI: 10.1177/0269881116675783
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedinst
Journal of Psychopharmacology, 2016, 30, 1181–1197. DOI: 10.1177/0269881116675513
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E. Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby, Brian L. Schmidt
Journal of Psychopharmacology, 2016, 30, 1165–1180. DOI: 10.1177/0269881116675512
Psilocybin for depression and anxiety associated with life-threatening illnesses
John D McCorvy, Reid HJ Olsen, Bryan L Roth
Journal of Psychopharmacology, 2016, 30, 1209–1210. DOI: 10.1177/0269881116675771
Psycho-existential distress in cancer patients: A return to “entheogens”
Craig D Blinderman
Journal of Psychopharmacology, 2016, 30, 1205–1206. DOI: 10.1177/0269881116675761
The role of psychedelics in palliative care reconsidered: A case for psilocybin
Benjamin Kelmendi, Philip Corlett, Mohini Ranganathan, Cyril D’Souza, John H. Krystal
Journal of Psychopharmacology, 2016, 30, v tisku. DOI: 10.1177/0269881116675781
Serotonergic Hallucinogen-Induced Visual Perceptual Alterations
Michael Kometer, Franz X. Vollenweider
Current Topics in Behavioral Neurosciences, 2016, v tisku. DOI: 10.1007/7854_2016_461
Phenomenology, Structure, and Dynamic of Psychedelic States
Katrin H. Preller, Franz X. Vollenweider
Current Topics in Behavioral Neurosciences, 2016, v tisku. DOI: 10.1007/7854_2016_459
Can 3,4,-methylenedioxymethamphetamine therapy be used to treat alcohol use disorder?
Ben Sessa
Journal of Psychedelic Studies, 2016, v tisku. DOI: 10.1556/2054.01.2016.003
Treating drug dependence with the aid of ibogaine: A qualitative study
Eduardo Ekman Schenberg, Maria Angélica de Castro Comis, João Felipe Morel Alexandre, Bruno Daniel Rasmussen Chaves, Luís Fernando Tófoli, Dartiu Xavier da Silveira
Journal of Psychedelic Studies, 2016, v tisku. DOI: 10.1556/2054.01.2016.002
The antiaddictive effects of ibogaine: A systematic literature review of human studies
RG dos Santos, JC Bouso, JEC Hallak
Journal of Psychedelic Studies, 2016, v tisku. DOI: 10.1556/2054.01.2016.001
Effects of the Natural β-Carboline Alkaloid Harmine, a Main Constituent of Ayahuasca, in Memory and in the Hippocampus: A Systematic Literature Review of Preclinical Studies
Rafael G. dos Santos, Jaime E. C. Hallak
Journal of Psychoactive Drugs, 2016, v tisku. DOI: 10.1080/02791072.2016.1260189
pregledni članek
Harmine stimulates proliferation of human neural progenitors
Vanja Dakic, Renata de Moraes Maciel, Hannah Drummond, Juliana M. Nascimento, Pablo Trindade, Stevens K. Rehen
PeerJ, 2016, 4:e2727. DOI: 10.7717/peerj.2727
Back to the future: Research renewed on the clinical utility of psychedelic drugs
Jeffrey A Lieberman, Daniel Shalev
Journal of Psychopharmacology, 2016, 30, 1198-1200. DOI: 10.1177/0269881116675755
Arylcyclohexamines (Ketamine, Phencyclidine, and Analogues)
James H. Ho, Paul I. Dargan
Critical Care Toxicology, 2016, 91–46. DOI: 10.1007/978-3-319-20790-2_124-1
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms
Frederick S Barrett, Matthew P. Bradstreet, Jeannie-Marie S Leoutsakos, Matthew W. Johnson, Roland R. Griffiths
J. Psychopharmacol., 2016, 30, 1279–1295. DOI: 10.1177/0269881116678781
Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology
Ido Hartogsohn
J. Psychopharmacol., 2016, 30, 1259–1267. DOI: 10.1177/0269881116677852
A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD
John H. Halpern, Arturo G. Lerner, Torsten Passie
Current Topics in Behavioral Neurosciences, 2016, 1-28. DOI: 10.1007/7854_2016_457
Classical hallucinogens and neuroimaging: a systematic review of human studies: Hallucinogens and neuroimaging
Rafael G. dos Santos, Flávia L. Osório, José Alexandre S. Crippaa, Jaime E.C. Hallak
Neuroscience & Biobehavioral Reviews, 2016, 71, 715–728. DOI: 10.1016/j.neubiorev.2016.10.026
Of Roots and Fruits: A Comparison of Psychedelic and Nonpsychedelic Mystical Experiences
David B. Yaden, Khoa D. Le Nguyen, Margaret L. Kern, Alexander B. Belser, Johannes C. Eichstaedt, Jonathan Iwry, Mary E. Smith, Nancy A. Wintering, Ralph W. Hood Jr., Andrew B. Newberg
Journal of Humanistic Psychology, 2016, v tisku. DOI: 10.1177/0022167816674625
Psychedelics in the treatment of unipolar mood disorders: A systematic review
J. Rucker, L. A. Jelen, S. Flynn, K. D. Frowde, A. Young
Journal of Psychopharmacology, 2016, v tisku.
Classic Psychedelics and Rational Suicide in the Elderly: Exploring the Potential Utility of a Reemerging Treatment Paradigm
Peter S. Hendricks, Charles S. Grob
DOI: 10.1007/978-3-319-32672-6_14
v: Rational Suicide in the Elderly, 2016, ur. R. E. McCue, M. Balasubramaniam, str. 203-210 (Springer).
Lysergic Acid Diethylamide and mystical experiences
Michael Lyvers
DOI: 10.1016/B978-0-12-800212-4.00078-9
v: The neuropathology of drug addictions and substance misuse (Vol 2), 2016, ur. V. Preedy, str. 835-845 (Elsevier).
The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization
Ede Frecska, Petra Bokor, Michael Winkelman
Front. Pharmacol., 2016, 7, e35. DOI: 10.3389/fphar.2016.00035
pregledni članek
Medicine, religion and ayahuasca in Catalonia. Considering ayahuasca networks from a medical anthropology perspective
Ismael Apud, Oriol Romaní
International Journal of Drug Policy, 2016, 39, 28-36. DOI: 10.1016/j.drugpo.2016.07.011
Creativity and Psychoactive Substance Use: A Systematic Review
Fruzsina Iszáj, Mark D. Griffiths, Zsolt Demetrovics
J. Ment. Health Addiction, 2016, v tisku. DOI: 10.1007/s11469-016-9709-8
pregledni članek
Transcultual Perspective on Consciousness: Traditional Use of Ayahuasca in Psychiatry in the 21st Century in the Western World
T. Re, J. Palma, J. E. Martins, M. Simões
Cosmos and History: The Journal of Natural and Social Philosophy, 2016, 12, 237-249.
The ethnobotany of psychoactive plant use: a phylogenetic perspective
Nashmiah Aid Alrashedy, Jeanmaire Molina
PeerJ, 2016, 4, e2546. DOI: 10.7717/peerj.2546
Alterations of consciousness and mystical-type experiences after acute LSD in humans
Matthias E. Liechti, Patrick C. Dolder, Yasmin Schmid
Psychopharmacology, 2016, v tisku. DOI: 10.1007/s00213-016-4453-0
The Transpersonal Potential of Psychedelics
C. W. Angelo
v: Shadows & Light (Volume 1: Principles & Practices): Theory, Research, and Practice in Transpersonal Psychology, 2016, ur. F. J. Kaklauskas, C. J. Clements, D. Hocoy, L. Hoffman (University Professors Press).
Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism
Michael P. Bogenschutz, Alyssa A. Forcehimes
Journal of Humanistic Psychology, 2016, v tisku. DOI: 10.1177/0022167816673493
Ecstatic Landscapes: The Manifestation of Psychedelic Art
Stanley Krippner
Journal of Humanistic Psychology, 2016, v tisku. DOI: 10.1177/0022167816671579
Psychedelic Psychotherapy: Insights From 25 Years of Research
William A. Richards
Journal of Humanistic Psychology, 2016, v tisku. DOI: 10.1177/0022167816670996
Abraham Maslow’s Interest in Psychedelic Research: A Tribute
William A. Richards
Journal of Humanistic Psychology, 2016, v tisku. DOI: 10.1177/0022167816670997
Ayahuasca Treatment Center Safety for the Western Seeker
Raven Renèe Ray, Kerry S. Lassiter
Anthropology of Consciousness, 2016, 27, 121–150. DOI: 10.1111/anoc.12060
The Globalization of Ayahuasca Shamanism and the Erasure of Indigenous Shamanism
Evgenia Fotiou
Anthropology of Consciousness, 2016, 27, 151–179. DOI: 10.1111/anoc.12056
The Revitalization of Yajé Shamanism among the Siona: Strategies of Survival in Historical Context
Esther Jean Langdon
Anthropology of Consciousness, 2016, 27, 180–203. DOI: 10.1111/anoc.12058
Ayahuasca and Sumak Kawsay: Challenges to the Implementation of the Principle of “Buen Vivir,” Religious Freedom, and Cultural Heritage Protection
Carlos Teodoro J. H. Irigaray, Pierre Girard, Maíra Irigaray, Carolina Joana da Silva
Anthropology of Consciousness, 2016, 27, 204–225. DOI: 10.1111/anoc.12057
Psychological and neuropsychological assessment of regular hoasca users
Paulo Cesar Ribeiro Barbosa, Rick J. Strassman, Dartiu Xavier da Silveira, Kelsy Areco, Robert Hoya, Jessica Pommya, Robert Thoma, Michael Bogenschutz
Comprehensive Psychiatry, 2016, 71, 95–105. DOI: 10.1016/j.comppsych.2016.09.003
The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells
Attila Szabo, Attila Kovacs, Jordi Riba, Srdjan Djurovic, Eva Rajnavolgyi, Ede Frecska
Front. Neurosci., 2016, 10, 423. DOI: 10.3389/fnins.2016.00423
Sacred Bliss: A Spiritual History of Cannabis
Mark S. Ferrara, 2016 (Rowman & Littlefield). (google books preview)
Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis
R. M. Murray, H. Quigley, D. Quattrone, A. Englund, M. Di Forti
World Psychiatry, 15, 195–204. DOI: 10.1002/wps.20341
pregledni članek
Psychedelics Recruit Multiple Cellular Types and Produce Complex Transcriptional Responses Within the Brain
David A. Martin, Charles D. Nichols
EBioMedicine, 2016, 11, 262–277. DOI: 10.1016/j.ebiom.2016.08.049
The Discriminative Stimulus Properties of Hallucinogenic and Dissociative Anesthetic Drugs
Tomohisa Mori, Tsutomu Suzuki
Current Topics in Behavioral Neurosciences, 2016, 1-12. DOI: 10.1007/7854_2016_29
Brazil’s Ayahuasca Religions: Comparisons and Contrasts
A. Dawson
v: Handbook of Contemporary Religions in Brazil, 2016, ur. B. Schmidt, S. Engler, str. 233-252 (Brill). (google books preview)
The World Ayahuasca Diaspora: Reinventions and Controversies
ur. Beatriz Caiuby Labate, Clancy Cavnar, Alex K. Gearin, 2017 (Routledge). (google books preview)
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences
Theresa M. Carbonaro, Matthew P. Bradstreet, Frederick S. Barrett, Katherine A. MacLean, Robert Jesse, Matthew W. Johnson, Roland R. Griffiths
J. Psychopharmacol., 2016, 30, 1268-1278. DOI: 10.1177/0269881116662634
Medijske interpretacije: Researchers Urge Caution around Psilocybin Use;
Is There a Place for Psychedelics in Philosophy?: Fieldwork in Neuro- and Perennial Philosophy
Nicolas Langlitz
Common Knowledge, 2016, 22, 373-384. DOI: 10.1215/0961754X-3622224
Ketamine-Assisted Psychedelic Therapy
E. M. Krupitsky, A. I. Paley, T. N. Berkaliev, V. B. Ivanov, O. O. Dubrovina, D. A. Kozhnazarova, I. V. Dunaevsky, E. V. Rzhankova, A. Ya. Grinenko
International Journal of Transpersonal Studies, 2016, 15, 24-40.
pregledni članek
The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies
Yosta Vegting, Liesbeth Reneman, Jan Booij
Psychopharmacology, 2016, 233, 3473–3501. DOI: 10.1007/s00213-016-4396-5
pregledni članek
Return of the psychedelics: Psilocybin for treatment resistant depression
Suravi Patra
Asian Journal of Psychiatry, 2016, 24, 51–52. DOI: 10.1016/j.ajp.2016.08.010
pregledni članek
5-HT2A/5-HT2C Receptor Pharmacology and Intrinsic Clearance of N-Benzylphenethylamines Modified at the Primary Site of Metabolism
Sebastian Leth-Petersen, Ida N. Petersen, Anders A. Jensen, Christoffer Bundgaard, Mathias Bæk, Jan Kehler, and Jesper L. Kristensen
ACS Chem. Neurosci., 2016, 7, 1614–1619. DOI: 10.1021/acschemneuro.6b00265
The Entheogen Revolution
Thomas B. Roberts
The Journal of Transpersonal Psychology, 2016, 48, 26-33.
The antidepressant effect of ketamine: Mediated by AMPA receptors?
Dragos Inta, Rolf Sprengel, Stefan Borgwardt, Undine E. Lang, Peter Gass
European Neuropsychopharmacology, 2016, 26, 1692–1693. DOI: 10.1016/j.euroneuro.2016.08.002
The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors
Danilo De Gregorio, Luca Posa, Rafael Ochoa-Sanchez, Ryan McLaughlin, Sabatino Maione, Stefano Comai, Gabriella Gobbi
Pharmacological Research, 2016, 113, 81–91. DOI: 10.1016/j.phrs.2016.08.022
Quantification of Anti-Addictive Alkaloids Ibogaine and Voacangine in in vivo- and in vitro-Grown Plants of Two Mexican Tabernaemontana Species
F. Krengel, J. H. Santoyo, T. de Jesús Olivera Flores, V. M. Chávez Ávila, F. J. Pérez Flores, R. Reyes Chilpa
Chem Biodiversity, 2016, 13, 1730–1737. DOI: 10.1002/cbdv.201600146
Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients
P. Glue, G. Cape, D. Tunnicliff, M. Lockhart, F. Lam, N. Hung, C. T. Hung, S. Harland, J. Devane, R. S. Crockett, J. Howes, B. Darpo, M. Zhou, H. Weis, L. Friedhoff
Clinical pharmacology in Drug Development, 2016, 5, 460–468. DOI: 10.1002/cpdd.254
An intravenous self-administration procedure for assessing the reinforcing effects of hallucinogens in nonhuman primates
Amy K. Goodwin
Journal of Pharmacological and Toxicological Methods, 2016, 82, 31–36. DOI: 10.1016/j.vascn.2016.07.004
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
K. P. C. Kuypers, J. Riba, M. de la Fuente Revenga, S. Barker, E. L. Theunissen, J. G. Ramaekers
Psychopharmacology, 2016, 233, 3395. DOI: 10.1007/s00213-016-4377-8
A Public-Health-Based Vision for the Management and Regulation of Psychedelics
Mark Haden, Brian Emerson, Kenneth W. Tupper
Journal of Psychoactive Drugs, 2016, 48, 243-252. DOI: 10.1080/02791072.2016.1202459
Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics
L. F. Tófoli, D. B. de Araujo
International Review of Neurobiology, 2016, 129, 157–185. DOI: 10.1016/bs.irn.2016.06.005
Clinical applications of hallucinogens: A review
Albert Garcia-Romeu, Brennan Kersgaard, Peter H. Addy
Experimental and Clinical Psychopharmacology, 2016, 24, 229-268. DOI: 10.1037/pha0000084
Long-term follow-up of psilocybin-facilitated smoking cessation
Matthew W. Johnson, Albert Garcia-Romeu, Roland R. Griffiths
The American Journal of Drug and Alcohol Abuse, 2016, v tisku. DOI: 10.3109/00952990.2016.1170135
Medijske interpretacije: Can Magic Mushrooms Cure Addiction?; Live Every Day Like You’re on Mushrooms
What Neuroimaging of the Psychedelic State Tells Us about the Mind-Body Problem
Bernardo Kastrup
Journal of Cognition and Neuroethics, 2016, 4, 1–9.
From Psychiatry to Flower Power and Back Again: The Amazing Story of Lysergic Acid Diethylamide
Mucke Hermann A. M.
ASSAY and Drug Development Technologies, 2016, 14, 276-281. DOI: 10.1089/adt.2016.747
Ibogaine for treating drug dependence. What is a safe dose?
L. J. Schep, R. J. Slaughter, S. Galea, D. Newcombe
Drug and Alcohol Dependence, 2016, 166, 1–5. DOI: 10.1016/j.drugalcdep.2016.07.005
MDMA and PTSD Treatment
Ben Sessa
Neuroscience Letters, 2016, v tisku. DOI: 10.1016/j.neulet.2016.07.004
A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience
A. R. Gallimore, R. Strassman
Front. Pharmacol., 2016, 7, 211. DOI: 10.3389/fphar.2016.00211
Spirituality, drugs, and tourism: tourists’ and shamans’ experiences of ayahuasca in Iquitos, Peru
Girish Prayag, Paolo Mura, Colin Michael Hall, Julien Fontaine
Tourism Recreation Research, 2016, 41, 314-325. DOI: 10.1080/02508281.2016.1192237
Babyfat and Belladonna: Witches’ Ointment and the Contestation of Reality
Michael Ostling
Magic, Ritual, and Witchcraft, 2016, 11, 30-72. DOI: 10.1353/mrw.2016.0008
The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging
Rafael G. dos Santos, Fermanda M. Balthazar, José C. Bouso, Jaime E. C. Hallak
J. Psychopharmacol., 2016, 30, 1230 – 1247. DOI: 10.1177/0269881116652578
Hallucinating the Slovenian Way: The Myth of Salamander Brandy, an Indigenous Slovenian Psychedelic Drug
Miha Kozorog
v: Edible Identities: Food as Cultural Heritage, 2016, ur. Ronda L. Brulotte, Michael A. Di Giovine, str. 125-139 (Routledge). (google books preview)
Potential involvement of serotonergic signaling in ketamine’s antidepressant actions: A critical review
Kristian Gaarn du Jardin, Heidi Kaastrup Müller, Betina Elfving, Elena Dale, Gregers Wegener, Connie Sanchez
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 71, 27–38. DOI: 10.1016/j.pnpbp.2016.05.007
Ketamine abuse potential and use disorder
Y. Liu, D. Lin, B. Wu, W. Zhou
Brain Research Bulletin, 2016, 126, 68–73. DOI: 10.1016/j.brainresbull.2016.05.016
pregledni članek
Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans
Amanda A. Nunes, Rafael G. dos Santos, Flávia L. Osório, Rafael F. Sanches, José Alexandre S. Crippa, Jaime E. C. Hallak
Journal of Psychoactive Drugs, 2016, 48, 195-205. DOI: 10.1080/02791072.2016.1188225
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M. J. Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A. Rickard, Ben Forbes, Amanda Feilding, David Taylor, Steve Pilling, Valerie H. Curran, David J. Nutt
Lancet Psychiatry, 2016, 3, 619–627. DOI: 10.1016/S2215-0366(16)30065-7
Medijske interpretacije: Magic mushroom ingredient offers hope for treating depression
Prohibited or regulated? LSD psychotherapy and the United States Food and Drug Administration
Matthew Oram
History of Psychiatry, 2016, 27, 290-306. DOI: 10.1177/0957154X16648822
Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report
L. Cloutier-Gill, E. Wood, T. Millar, C. Ferris, M. Eugenia Socias
Journal of Psychoactive Drugs, 2016, 48, 214-217. DOI: 10.1080/02791072.2016.1180467
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Anna Rickli, Olivier D. Moning, Marius C. Hoener, Matthias E. Liecht
European Neuropsychopharmacology, 2016, 26, 1327–1337. DOI: 10.1016/j.euroneuro.2016.05.001
Chemical Constituents of Plants from the Genus Psychotria
Hongmei Yang, Hongmei Zhang, Caiqiong Yang, Yegao Chen
Chemistry & Biodiversity, 2016, 13, 807–820. DOI: 10.1002/cbdv.201500259
Psychedelics Produce Complex And Heterogeneous Transcriptional Responses In Diverse Cortical Cell Types In The Brain Of Rats As Determined By New Flow Cytometric Methods Allowing For Sorting Of Distinct Cell And Neuronal Populations From Whole Brain
David Martin, Connie Porretta, Charles D. Nichols
FASEB J., 2016, 30, 930.3. DOI: 10.1096/fj.1530-6860
Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action
Joanna Ficek, Magdalena Zygmunt, Marcin Piechota, Dzesika Hoinkis, Jan Rodriguez Parkitna, Ryszard Przewlocki, Michal Korostynski
BMC Genomics, 2016, 17, 362. DOI: 10.1186/s12864-016-2713-3
Effects of low dose ibogaine on subjective mood state and psychological performance
Bridget Forsytha, Liana Machadoa, Tim Jowettb, Hannah Jakobic, Kira Garbec, Helen Winterd, Paul Glue
Journal of Ethnopharmacology, 2016, 189, 10–13. DOI: 10.1016/j.jep.2016.05.022
The paradoxical psychological effects of lysergic acid diethylamide (LSD)
R. L. Carhart-Harris, M. Kaelen, M. Bolstridge, T. M. Williams, L. T. Williams, R. Underwood, A. Feilding, D. J. Nutt
Psychological Medicine, 2016, 46, 1379-1390. DOI: 10.1017/S0033291715002901
Medijske interpretacije: Taking LSD leads to ‘improved psychological wellbeing’ – study; The psychedelic paradox; LSD: Psychedelic Thrill or Optimism Pill?
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Panos Zanos et al.
Nature, 2016, 533, 481–486. DOI: 10.1038/nature17998
Medijske interpretacije: Ketamine lifts depression via a byproduct of its metabolism
Practical application of the neuroregenerative properties of ketamine: real world treatment experience
T. A. Henderson
Neural. Regen. Res., 2016, 11, 195-200. DOI: 10.4103/1673-5374.177708
Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities
Joaquim Soler, Matilde Elices, Alba Franquesa, Steven Barker, Pablo Friedlander, Amanda Feilding, Juan C. Pascual, Jordi Riba
Psychopharmacology, 2016, 233, 823-829. DOI: 10.1007/s00213-015-4162-0
Has psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety
Keith G. Rasmussen
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 218–224. DOI: 10.1016/j.pnpbp.2015.01.002
LSD-induced entropic brain activity predicts subsequent personality change
A.V. Lebedev, M. Kaelen, M. Lövdén, J. Nilsson, A. Feilding, D.J. Nutt, R. L. Carhart-Harris
Human Brain Mapping, 2016, 37, 3203–3213. DOI: 10.1002/hbm.23234
LSD Alters Eyes-Closed Functional Connectivity within the Early Visual Cortex in a Retinotopic Fashion
Leor Roseman, Martin I. Sereno, Robert Leech, Mendel Kaelen, Csaba Orban, John McGonigle, Amanda Feilding, David J. Nutt, Robin L. Carhart-Harris
Human Brain Mapping, 2016, 37, 3031–3040. DOI: 10.1002/hbm.23224
Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use
Zach Walsh, Peter S. Hendricks, Stephanie Smith, David S. Kosson, Michelle S. Thiessen, Philippe Lucas, Marc T. Swogger
J. Psychopharmacol., 2016, 30, 601-607. DOI: 10.1177/0269881116642538
Medijske interpretacije: Psychedelic drugs may reduce domestic violence; Magic mushrooms and LSD may prevent domestic violence by providing ‘spiritual experiences’
Psychedelics
David Nichols
Pharmacological Reviews, 2016, 68, 264–355. DOI: 10.1124/pr.115.011478
(pregledni članek)
Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide
Jana Speth, Clemens Speth, Mendel Kaelen, Astrid M. Schloerscheidt, Amanda Feilding, David J. Nutt, Robin L. Carhart-Harris
J. Psychopharmacol, 2016, 30, 344-353. DOI: 10.1177/0269881116628430
Medijske interpretacije: Brain imaging study examines how LSD changes the way people think about time
LSD modulates music-induced imagery via changes in parahippocampal connectivity
Mendel Kaelen, Leor Roseman, Joshua Kahan, Andre Santos-Ribeiro, Csaba Orban, Romy Lorenz, Frederick S. Barrett, Mark Bolstridge, Tim Williams, Luke Williams, Matthew B. Wall, Amanda Feilding, Suresh Muthukumaraswamy, David J. Nutt, Robin Carhart-Harris
European Neuropsychopharmacology, 2016, 26, 1099–1109. DOI: 10.1016/j.euroneuro.2016.03.018
Medijske interpretacije: How to Pick Music for People on LSD, From a Scientist Whose Job That Is
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Robin L. Carhart-Harris, Suresh Muthukumaraswamy, Leor Roseman, Mendel Kaelen, Wouter Droog, Kevin Murphy, Enzo Tagliazucchi, Eduardo E. Schenberg, Timothy Nest, Csaba Orban, Robert Leech, Luke T. Williams, Tim M. Williams, Mark Bolstridge, Ben Sessa, John McGonigle, Martin I. Sereno, David Nichols, Peter J. Hellyer, Peter Hobden, John Evans, Krish D. Singh, Richard G. Wise, H. Valerie Curran, Amanda Feilding, David J. Nutt
Proceedings of the National Academy of Sciences, 2016, 113, 4853–4858. DOI: 10.1073/pnas.1518377113
Medijske interpretacije: For the First Time, Scientists Have Imaged the Brain on LSD; Brain on LSD revealed: First scans show how the drug affects the brain
Effects of serotonin 2A/1A receptor stimulation on social exclusion processing
Katrin H. Preller, Thomas Pokorny, Andreas Hock, Rainer Kraehenmann, Philipp Stämpfli, Erich Seifritz, Milan Scheidegger, Franz X. Vollenweider
Proceedings of the National Academy of Sciences, 2016, 113, 5119-5124. DOI: 10.1073/pnas.1524187113
Medijske interpretacije: Feeling rejected? Mushrooms could help; Magic mushrooms can help reduce the pain of social rejection
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults
Alicia L. Danforth, Christopher M. Struble, Berra Yazar-Klosinski, Charles S. Grob
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 237–249. DOI: 10.1016/j.pnpbp.2015.03.011
Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience
Thomas Pokorny, Katrin H. Preller, Rainer Kraehenmann, Franz X. Vollenweider
European Neuropsychopharmacology, 2016, 26, 756–766. DOI: 10.1016/j.euroneuro.2016.01.005
Classic hallucinogens in the treatment of addictions
Michael P. Bogenschutz, Matthew W. Johnson
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 250–258. DOI: 10.1016/j.pnpbp.2015.03.002
Psychedelics and cognitive liberty: Reimagining drug policy through the prism of human rights
Charlotte Walsh
International Journal of Drug Policy, 2016, 29, 80-87. DOI: 10.1016/j.drugpo.2015.12.025
The epistemic innocence of psychedelic states
Chris Letheby
Consciousness and Cognition, 2016, 39, 28–37. DOI: 10.1016/j.concog.2015.11.012
2015
LSD enhances the emotional response to music
M. Kaelen, F. S. Barrett, L. Roseman, R. Lorenz, N. Family, M. Bolstridge, H. V. Curran, A. Feilding, D. J. Nutt, R. L. Carhart-Harris
Psychopharmacology, 2015, 232, 3607-3614. DOI: 10.1007/s00213-015-4014-y
Psychedelic medicine: a re-emerging therapeutic paradigm
Kenneth W. Tupper, Evan Wood, Richard Yensen, Matthew W. Johnson
CMAJ, 2015, 187, 1054-1059. DOI: 10.1503/cmaj.141124
(pregledni članek)
Medijske interpretacije: Psychedelic medicine: a re-emerging therapeutic paradigm, PTSD and addiction; Psychedelic medicine is making a comeback
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Michael P Bogenschutz, Alyssa A. Forcehimes, Jessica A. Pommy, Claire E. Wilcox, P. C. R. Barbosa, Rick J Strassman
J. Psychopharmacol., 2015, 29, 289-299. DOI: 10.1177/0269881114565144
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population
Peter S. Hendricks, Christopher B. Thorne, C. Brendan Clark, David W. Coombs, Matthew W. Johnson
J. Psychopharmacol., 2015, 29, 280-288. DOI: 10.1177/0269881114565653
Psychedelics not linked to mental health problems or suicidal behavior: A population study
Pål-Ørjan Johansen, Teri Suzanne Krebs
J. Psychopharmacol, 2015, 29, 270-279. DOI: 10.1177/0269881114568039
Medijske interpretacije: No link found between psychedelics and psychosis; Psychedelic drug use ‘does not increase risk for mental health problems’; Seeing Opportunity in Psychedelic Drugs
Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans
José Carlos Bouso, Fernanda Palhano-Fontes, Antoni Rodríguez-Fornells, Sidarta Ribeiro, Rafael Sanches, José Alexandre S. Crippa, Jaime E.C. Hallak, Draulio B. de Araujo, Jordi Riba
European Neuropsychopharmacology, 2015, 25, 483–492. DOI: 10.1016/j.euroneuro.2015.01.008
Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential
James J. H. Rucker
BMJ, 2015, 350:h2902. DOI: 10.1136/bmj.h2902
Medijske interpretacije: Psychedelic drugs should be legally reclassified as they may benefit patients, experts say
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects
Peter Gasser, Katharina Kirchner, Torsten Passie
J. Psychopharmacol., 2015, 29, 57-68. DOI: 10.1177/0269881114555249
Serotonin 5-HT2 receptor activation prevents allergic asthma in a mouse model
Felix Nau Jr., Justin Miller, Jordy Saravia, Terry Ahlert, Bangning Yu, Kyle I. Happel, Stephania A. Cormier, Charles D. Nichols
American Journal of Physiology – Lung Cellular and Molecular Physiology, 2015, 308, L191-L198.
DOI: 10.1152/ajplung.00138.2013
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Adam L. Halberstadt
Behavioural Brain Research, 2015, 277, 99–120. DOI: 10.1016/j.bbr.2014.07.016
Can psychedelic compounds play a part in drug dependence therapy?
Ben Sessa, Matthew W. Johnson
British Journal of Psychiatry, 2015, 206, 1-3. DOI: 10.1192/bjp.bp.114.148031
Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities
Attila Szabo
Front Immunol. 2015, 6, 358. DOI: 10.3389/fimmu.2015.00358
Serotonergic Psychedelics Temporarily Modify Information Transfer in Humans
Joan Francesc Alonso, Sergio Romero, Miquel Àngel Mañanas, Jordi Riba
International Journal of Neuropsychopharmacology, 2015, 18, 1-9. DOI: 10.1093/ijnp/pyv039
Restructuring consciousness -the psychedelic state in light of integrated information theory
A. R. Gallimore
Frontiers in Human Neuroscience, 2015, 9, 346. DOI: 10.3389/fnhum.2015.00346
The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network
F. Palhano-Fontes, K. C. Andrade, L. F. Tofoli, A. C. Santos, J. A. Crippa, J. E. Hallak, S. Ribeiro, D. B. de Araujo
PLoS One, 2015, 10, e0118143. DOI: 10.1371/journal.pone.0118143
Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability
P. Glue, M. Lockhart, F. Lam, N. Hung, C.-T. Hung, L. Friedhoff
J. Clin. pharmacol., 2015, 55, 189-194. DOI: 10.1002/jcph.404
Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
T. Majić, T. T. Schmidt, J. Gallinat
J. Psychopharmacol., 2015, 29, 241-253. DOI: 10.1177/0269881114568040
New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca
D. McKenna D, J. Riba
Current Topics in Behavioral Neurosciences, 2015, 1-27. DOI: 10.1007/7854_2015_368
Salvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans
A. E. Maqueda, M. Valle M, P. H. Addy, R. M. Antonijoan. M. Puntes, J. Coimbra, M. R. Ballester, M. Garrido, M. Gonzalez, J. Claramunt, S. Barker, M. W. Johnson, R. R. Griffiths, J. Riba
International Journal of Neuropsychopharmacology, 2015, 18, pyv065. DOI: 10.1093/ijnp/pyv065
Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions
D. González, M. Torrens, M. Farré
Biomed Res Int., 2015, 643878. DOI: 10.1155/2015/643878
The Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series
Joseph El-Khoury, Nayiri Sahakian
Journal of Psychoactive Drugs, 2015, 47, 286-292. DOI: 10.1080/02791072.2015.1073815
Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin
Alexander V. Lebedev, Martin Lovden, Gidon Rosenthal, Amanda Feilding, David J. Nutt, Robin L. Carhart-Harris
Human Brain Mapping., 2015, 36, 3137-3153. DOI: 10.1002/hbm.22833
Mind navigators of chemicals’ experimenters? A web-based description of e-psychonauts
L. Orsolini, G. D. Papanti, G. Francesconi, F. Schifano
Cyberpsychol Behav Soc Netw., 2015, 18, 296-300. DOI: 10.1089/cyber.2014.0486
2014
Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction
Albert Garcia-Romeu, Roland R. Griffiths, Matthew W Johnson
Current Drug Abuse Reviews, 2014, 7, 157-164. DOI: 10.2174/1874473708666150107121331
Ayahuasca, Psychedelic Studies and Health Sciences: The Politics of Knowledge and Inquiry into an Amazonian Plant Brew
Kenneth W. Tupper, Beatriz C Labate
Current Drug Abuse Reviews, 2014, 7, 71-80. DOI: 10.2174/1874473708666150107155042
Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca
Michael Winkelman
Current Drug Abuse Reviews, 2014, 7, 101-116. DOI: 10.2174/1874473708666150107120011
A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects
Mitchell B Liester
Current Drug Abuse Reviews, 2014, 7, 146-156. DOI: 10.2174/1874473708666150107120522
A Qualitative Report on the Subjective Experience of Intravenous Psilocybin Administered in an fMRI Environment
S. Turton, D. J. Nutt, R. L. Carhart-Harris.
Current Drug Abuse Reviews, 2014, 7, 117-127. DOI: 10.2174/1874473708666150107120930
Salvinorin A and Related Compounds as Therapeutic Drugs for Psychostimulant-Related Disorders
R. G. dos Santos, J. A. S. Crippa, J. P. Machado-de-Sousa, J. E. C. Hallak.
Current Drug Abuse Reviews, 2014, 7, 128-132. DOI: 10.2174/1874473708666150107122741
What Can Neuroscience Tell Us About the Potential of Psychedelics in Healthcare? How the Neurophenomenology of Psychedelics Research Could Help us to Flourish Throughout Our Lives, as Well as to Enhance Our Dying
Robin Mackenzie
Current Drug Abuse Reviews, 2014, 7, 136-145. DOI: 10.2174/1874473708666150107114927
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
Matthew W Johnson, Albert Garcia-Romeu, Mary P. Cosimano, Roland R. Griffiths
J. Psychopharmacol., 2014, 28, 983-992. DOI: 10.1177/0269881114548296
Psilocybin and Obsessive Compulsive Disorder
James Allen Wilcox
Journal of Psychoactive Drugs, 2014, 46, 393-395. DOI: 10.1080/02791072.2014.963754
Immunological Effects of Ayahuasca in Humans
Rafael Guimarães dos Santos
Journal of Psychoactive Drugs, 2014, 46, 383-388. DOI: 10.1080/02791072.2014.960113
Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles
David Baumeister, Georgina Barnes, Giovanni Giaroli, Derek Tracy
Therapeutic Advances in Psychopharmacology, 2014, 4, 156-169. DOI: 10.1177/2045125314527985
(pregledni članek)
Enhanced repertoire of brain dynamical states during the psychedelic experience
E. Tagliazucchi, R. Carhart-Harris, R. Leech, D. Nutt, D. R. Chialvo
Hum. Brain Mapp., 2014, 35, 5442–5456. DOI: 10.1002/hbm.22562
The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers
Leor Roseman, Robert Leech, Amanda Feilding, David J. Nutt, Robin L. Carhart-Harris
Front. Hum. Neurosci., 2014, 8, 1-11. DOI: 10.3389/fnhum.2014.00204
Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers
Rainer Kraehenmann, Katrin H. Preller, Milan Scheidegger, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz, Franz X. Vollenweider
Biological Psychiatry, 2015, 78, 572–581. DOI: 10.1016/j.biopsych.2014.04.010
From Hofmann to the Haight Ashbury, and into the Future: The Past and Potential of Lysergic Acid Diethlyamide
David E. Smith, Glenn E. Raswyck, Leigh Dickerson Davidson
Journal of Psychoactive Drugs, 2014, 46, 3-10. DOI: 10.1080/02791072.2014.873684
Self-Experimentations with Psychedelics Among Mental Health Professionals: LSD in the Former Czechoslovakia
Petr Winkler, Ladislav Csémy
Journal of Psychoactive Drugs, 2014, 46, 11-19. DOI: 10.1080/02791072.2013.873158
The Heffter Research Institute: Past and Hopeful Future
David E. Nichols
Journal of Psychoactive Drugs, 2014, 46, 20-26. DOI: 10.1080/02791072.2014.873688
History and Future of the Multidisciplinary Association for Psychedelic Studies (MAPS)
Amy Emerson, Linnae Ponté, Lisa Jerome, Rick Doblin
Journal of Psychoactive Drugs, 2014, 46, 27-36. DOI: 10.1080/02791072.2014.877321
The Potential Dangers of Using MDMA for Psychotherapy
Andrew C. Parrott
Journal of Psychoactive Drugs, 2014, 46, 37-43. DOI: 10.1080/02791072.2014.873690
MDMA and the “Ecstasy Paradigm”
Jon C. Cole Ph.D.
Journal of Psychoactive Drugs, 2014, 46, 44-56. DOI: 10.1080/02791072.2014.878148
Why Psychiatry Needs Psychedelics and Psychedelics Need Psychiatry
Ben Sessa
Journal of Psychoactive Drugs, 2014, 46, 57-62. DOI: 10.1080/02791072.2014.877322
Therapeutic Effects of Ritual Ayahuasca Use in the Treatment of Substance Dependence—Qualitative Results
Anja Loizaga-Velder, Rolf Verres
Journal of Psychoactive Drugs, 2014, 46, 63-72. DOI: 10.1080/02791072.2013.873157
PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program
George R. Greer, Charles S. Grob, Adam L. Halberstadt
Journal of Psychoactive Drugs, 2014, 46, 73-77. DOI: 10.1080/02791072.2013.873843
Psilocybin – Summary of knowledge and new perspectives
Filip Tylš, Tomáš Páleníček, Jiří Horáček
European Neuropsychopharmacology, 2014, 24, 342–356. DOI: 10.1016/j.euroneuro.2013.12.006
(pregledni članek)
2013
Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada
Gerald Thomas, Philippe Lucas, N. Rielle Capler, Kenneth W. Tupper, Gina Martin
Current Drug Abuse Reviews, 2013, 6, 30-42. DOI: 10.2174/15733998113099990003
Ibogaine in the Treatment of Substance Dependence
Thomas Kingsley Brown
Current Drug Abuse Reviews, 2013, 6, 3-16. DOI: 10.2174/15672050113109990001
Can MDMA Play a Role in the Treatment of Substance Abuse?
Lisa Jerome, Shira Schuster, B Berra Yazar-Klosinski.
Current Drug Abuse Reviews, 2013, 6, 54-62. DOI: 10.2174/18744737112059990005
Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin
Michael P Bogenschutz
Current Drug Abuse Reviews, 2013, 6, 17-29. DOI: 10.2174/15733998113099990002
Psychedelics and Mental Health: A Population Study
Teri S. Krebs, Pål-Ørjan Johansen
Plos One, 2016, 8, e63972. DOI: 10.1371/journal.pone.0063972
Medijske interpretacije: Data from U.S. survey casts doubt on U.S. classification of psychedelics as ‘dangerous’
Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants
Caroline A. Browne, Irwin Lucki
Front. Pharmacol., 2013, 4, 161. DOI: 10.3389/fphar.2013.00161
Multiple conformations of 5-HT2A and 5-HT2C receptors in rat brain: an autoradiographic study with [125I](±)DOI
Juan F. López-Giménez, M. Teresa Vilaró, José M. Palacios, Guadalupe Mengod
Experimental Brain Research, 2013, 230, 395-406. DOI: 10.1007/s00221-013-3636-8
LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate
Steven A. Barker, Jimo Borjigin, Izabela Lomnicka, Rick Strassman
Biomedical Chromatography, 2013, 27, 1690–1700. DOI: 10.1002/bmc.2981
Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties
P. A. Zunszain, M. A. Horowitz, A. Cattaneo, M. M. Lupi, C. M. Pariante
Molecular Psychiatry, 2013, 18, 1236–1241. DOI: 10.1038/mp.2013.87
2012
Research on psychedelic substances
Simon D. Brandt, Torsten Passie
Drug Testing and Analysis, 2012, 4, 539–542. DOI: 10.1002/dta.1389
Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses
Michael P. Bogenschutz, Jessica M. Pommy
Drug Testing and Analysis, 2012, 4, 543–555. DOI: 10.1002/dta.1376
Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model
Clint E. Canal, Drake Morgan
Drug Testing and Analysis, 2012, 4, 556–576.DOI: 10.1002/dta.1333
Fluorine in psychedelic phenethylamines
Daniel Trachsel
Drug Testing and Analysis, 2012, 4, 577–590. DOI: 10.1002/dta.413
GC-MS and GC-IRD studies on brominated dimethoxyamphetamines: Regioisomers related to 4-Br-2,5-DMA (DOB)
Hadir M. Maher, Tamer Awad, Jack DeRuiter, C. Randall Clark
Drug Testing and Analysis, 2012, 4, 591–600. DOI: 10.1002/dta.409
Health status of ayahuasca users
Paulo Cesar Ribeiro Barbosa, Suely Mizumoto, Michael P. Bogenschutz and Rick J. Strassman
Drug Testing and Analysis, 2012, 4, 601–609. DOI: 10.1002/dta.1383
Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca
Jordi Riba, Ethan H. McIlhenny, Marta Valle, José Carlos Bouso, Steven A. Barker
Drug Testing and Analysis, 2012, 4, 610–616. DOI: 10.1002/dta.1344
A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955–2010
Steven A. Barker, Ethan H. McIlhenny, Rick Strassman
Drug Testing and Analysis, 2012, 4, 617–635. DOI: 10.1002/dta.422
Analytical techniques for the determination of tryptamines and β-carbolines in plant matrices and in psychoactive beverages consumed during religious ceremonies and neo-shamanic urban practices
Alain Gaujac, Sandro Navickiene, Mark I. Collins, Simon D. Brandt, Jailson Bittencourt de Andrade
Drug Testing and Analysis, 2012, 4, 636–648. DOI: 10.1002/dta.1343